BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [PMID: 17567829 DOI: 10.1002/hep.21669] [Cited by in Crossref: 1256] [Cited by in F6Publishing: 1072] [Article Influence: 78.5] [Reference Citation Analysis]
Number Citing Articles
1 Hassoun S, Bruckmann C, Ciardullo S, Perseghin G, Di Gaudio F, Broccolo F. Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort. Int J Med Inform 2023;170:104932. [PMID: 36459836 DOI: 10.1016/j.ijmedinf.2022.104932] [Reference Citation Analysis]
2 Chang D, Truong E, Mena EA, Pacheco F, Wong M, Guindi M, Todo TT, Noureddin N, Ayoub W, Yang JD, Kim IK, Kohli A, Alkhouri N, Harrison S, Noureddin M. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. Hepatology 2023;77:546-57. [PMID: 35809234 DOI: 10.1002/hep.32655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Younossi Z, Alkhouri N, Cusi K, Isaacs S, Kanwal F, Noureddin M, Loomba R, Ravendhran N, Lam B, Nader K, Racila A, Nader F, Henry L. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2023;57:304-12. [PMID: 36511349 DOI: 10.1111/apt.17346] [Reference Citation Analysis]
4 Larrey D, D'Erasmo L, O'Brien S, Arca M; Italian Working Group on Lomitapide. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia. Liver Int 2023;43:413-23. [PMID: 36520008 DOI: 10.1111/liv.15497] [Reference Citation Analysis]
5 Wang C, Huang Y, Liu C, Liu F, Hu X, Kuang X, An W, Liu C, Liu Y, Liu S, He R, Wang H, Qi X. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model. Radiology 2023;:221648. [PMID: 36719293 DOI: 10.1148/radiol.221648] [Reference Citation Analysis]
6 Omar H, Waked I, Elakel W, Salama R, Abdel-Razik W, Elmakhzangy H, Abdel-Rahman YO, Saeed R, Elshafaey A, Ziada DH, Ismail SA, Dabbous HM, Esmat G. Evolution of liver fibrosis after interferon-based anti-hepatitis C virus therapy failure in 3,049 chronic hepatitis C patients without cirrhosis. Arab J Gastroenterol 2023:S1687-1979(23)00003-5. [PMID: 36725374 DOI: 10.1016/j.ajg.2023.01.002] [Reference Citation Analysis]
7 Alonso-bernáldez M, Cuevas-sierra A, Micó V, Higuera-gómez A, Ramos-lopez O, Daimiel L, Dávalos A, Martínez-urbistondo M, Moreno-torres V, Ramirez de Molina A, Vargas JA, Martinez JA. An Interplay between Oxidative Stress (Lactate Dehydrogenase) and Inflammation (Anisocytosis) Mediates COVID-19 Severity Defined by Routine Clinical Markers. Antioxidants 2023;12:234. [DOI: 10.3390/antiox12020234] [Reference Citation Analysis]
8 Ding C, Jia J, Han L, Zhou W, Liu Z, Bai G, Wang Q. Developing and validating a nomogram based on skeletal muscle index and clinical scoring system for prediction of liver failure after hepatectomy. Front Oncol 2023;13:1036921. [PMID: 36741004 DOI: 10.3389/fonc.2023.1036921] [Reference Citation Analysis]
9 Lee Y, Bae S, Kim JH, Kwak M, Jeon SY, Kim T, Yim SY, Lee YS, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study. J Clin Med 2023;12. [PMID: 36675640 DOI: 10.3390/jcm12020712] [Reference Citation Analysis]
10 Park SB, Jeon JW, Shin HP. The Risk of Endoscopy-Related Bleeding in Patients with Liver Cirrhosis: A Retrospective Study. Medicina (Kaunas) 2023;59. [PMID: 36676794 DOI: 10.3390/medicina59010170] [Reference Citation Analysis]
11 Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M, Sasaki-Tanaka R, Masuzaki R, Kanezawa S, Nishizawa T, Gon Y, Ogawa M, Kogure H. Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare. Viruses 2023;15:183. [PMID: 36680223 DOI: 10.3390/v15010183] [Reference Citation Analysis]
12 Canillas L, Pelegrina A, Álvarez J, Colominas-González E, Salar A, Aguilera L, Burdio F, Montes A, Grau S, Grande L, Carrión JA. Clinical Guideline on Perioperative Management of Patients with Advanced Chronic Liver Disease. Life (Basel) 2023;13. [PMID: 36676081 DOI: 10.3390/life13010132] [Reference Citation Analysis]
13 Ezpeleta M, Gabel K, Cienfuegos S, Kalam F, Lin S, Pavlou V, Song Z, Haus JM, Koppe S, Alexandria SJ, Tussing-Humphreys L, Varady KA. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab 2023;35:56-70.e3. [PMID: 36549296 DOI: 10.1016/j.cmet.2022.12.001] [Reference Citation Analysis]
14 Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, Younossi Z. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. Aliment Pharmacol Ther 2023;57:215-23. [PMID: 36369643 DOI: 10.1111/apt.17301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pugliese N, Alfarone L, Arcari I, Giugliano S, Parigi TL, Rescigno M, Lleo A, Aghemo A. Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Rev Gastroenterol Hepatol 2023;17:31-43. [PMID: 36576057 DOI: 10.1080/17474124.2023.2162503] [Reference Citation Analysis]
16 Yang R, Gui X, Ke H, Yu X, Yan Y, Xiong Y. Accuracy of FIB-4 and APRI scores compared to transient elastography for liver fibrosis in patients with HIV and HBV co-infection. Int J STD AIDS 2023;34:18-24. [PMID: 36426829 DOI: 10.1177/09564624221116530] [Reference Citation Analysis]
17 Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Tani J, Shi T, Himoto T, Tatsuta M, Moriya A, Senoo T, Tsutsui A, Nagano T, Takaguchi K, Ono M, Masaki T. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 2022. [PMID: 36583842 DOI: 10.1007/s12072-022-10453-1] [Reference Citation Analysis]
18 Kuwano A, Yada M, Kurosaka K, Tanaka K, Masumoto A, Motomura K. Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection. JGH Open 2022. [DOI: 10.1002/jgh3.12855] [Reference Citation Analysis]
19 Mücke VT, Fischer J, Mücke MM, Teumer A, Koch A, Vermehren J, Fromme M, Zeuzem S, Trautwein C, Sarrazin C, Berg T, Zhou B, Hamesch K. Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts. J Clin Med 2022;12. [PMID: 36615054 DOI: 10.3390/jcm12010253] [Reference Citation Analysis]
20 Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS One 2022;17:e0279416. [PMID: 36542633 DOI: 10.1371/journal.pone.0279416] [Reference Citation Analysis]
21 Nah EH, Shin SK, Cho S, Park H, Kim S, Kwon E, Cho HI. Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea. PLoS One 2022;17:e0279367. [PMID: 36538567 DOI: 10.1371/journal.pone.0279367] [Reference Citation Analysis]
22 Bian D, Zhao J, Liao H, Wang Y, Ren Y, Jiang Y, Liu S, Chen X, Hu Z, Duan Z, Lu F, Zheng S. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat 2022. [PMID: 36533536 DOI: 10.1111/jvh.13790] [Reference Citation Analysis]
23 Huang J, Yu J, Wang J, Liu J, Xie W, Li R, Wang C. Novel potential biomarkers for severe alcoholic liver disease. Front Immunol 2022;13:1051353. [PMID: 36582223 DOI: 10.3389/fimmu.2022.1051353] [Reference Citation Analysis]
24 Weigand K, Peschel G, Grimm J, Müller M, Höring M, Krautbauer S, Liebisch G, Buechler C. HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV. Biomedicines 2022;10. [PMID: 36551908 DOI: 10.3390/biomedicines10123152] [Reference Citation Analysis]
25 Tatoli R, Tirelli S, Lampignano L, Castellana F, Bortone I, Zupo R, Sborgia G, Lozupone M, Panza F, Giannelli G, Quaranta N, Boeing H, Sardone R. Liver Fibrosis and Hearing Loss in an Older Mediterranean Population: Results from the Salus in Apulia Study. J Clin Med 2022;11. [PMID: 36498787 DOI: 10.3390/jcm11237213] [Reference Citation Analysis]
26 Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018. Liver Int 2022;42:2646-61. [PMID: 36161464 DOI: 10.1111/liv.15437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gunsaulus M, Wang L, Haack L, Christopher A, Feingold B, Squires J, Horslen S, Hoskoppal A, Rose-felker K, West S, Trucco S, Squires J, Olivieri L, Kreutzer J, Goldstein B, Alsaied T. Cardiac MRI-Derived Inferior Vena Cava Cross-Sectional Area Correlates with Measures of Fontan-Associated Liver Disease. Pediatr Cardiol 2022. [DOI: 10.1007/s00246-022-03054-0] [Reference Citation Analysis]
28 Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-astagneau E, Mathurin P, Marcellin F, Petrov-sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C, Alric L, Pomes C, Zoulim F, Maynard M, Bai R, Hucault L, Bailly F, Raffi F, Billaud E, Boutoille D, Lefebvre M, André-garnier E, Cales P, Hubert I, Lannes A, Lunel F, Boursier J, Asselah T, Boyer N, Giuily N, Castelnau C, Scoazec G, Pol S, Fontaine H, Rousseaud E, Vallet-pichard A, Sogni P, de Ledinghen V, Foucher J, Hiriart J, M’bouyou J, Irlès-depé M, Bourlière M, Ahmed SNS, Oules V, Tran A, Anty R, Gelsi E, Truchi R, Thabut D, Hammeche S, Moussali J, Causse X, De Dieuleveult B, Ouarani B, Labarrière D, Ganne N, Grando-lemaire V, Nahon P, Brulé S, Ulker B, Guyader D, Jezequel C, Brener A, Laligant A, Rabot A, Renard I, Habersetzer F, Baumert TF, Doffoel M, Mutter C, Simo-noumbissie P, Razi E, Bronowicki J, Barraud H, Bensenane M, Nani A, Hassani-nani S, Bernard M, Pageaux G, Larrey D, Meszaros M, Metivier S, Bureau C, Morales T, Peron JM, Robic MA, Decaens T, Faure M, Froissart B, Hilleret M, Zarski J, Riachi G, Goria O, Paris F, Montialoux H, Leroy V, Amaddeo G, Varaut A, Simoes M, Amzal R, Chazouillières O, Andreani T, Angoulevant B, Chevance A, Serfaty L, Samuel D, Antonini T, Coilly A, Duclos-vallée J, Tateo M, Abergel A, Reymond M, Brigitte C, Benjamin B, Muti L, Geist C, Conroy G, Riffault R, Rosa I, Barrault C, Costes L, Hagège H, Loustaud-ratti V, Carrier P, Debette-gratien M, Mathurin P, Lassailly G, Lemaitre E, Canva V, Dharancy S, Louvet A, Minello A, Latournerie M, Bardou M, Mouillot T, D’alteroche L, Barbereau D, Nicolas C, Elkrief L, Jaillais A, Gournay J, Chevalier C, Archambeaud I, Habes S, Portal I, Gelu-simeon M, Saillard E, Lafrance M, Catherine L, Carrat F, Chau F, Dorival C, Goderel I, Lusivika-nzinga C, Bellance M, Bellet J, Monfalet P, Chane-teng J, Bijaoui S, Pannetier G, Téoulé F, Nicol J, Sebal F, Bekhti R, Cagnot C, Boston A, Nailler L, Le Meut G, Diallo A, Petrov-sanchez V, Bourlière M, Boursier J, Carrat F, Carrieri P, Delarocque-astagneau E, De Ledinghen V, Dorival C, Fontaine H, Fourati S, Housset C, Larrey D, Nahon P, Pageaux G, Petrov-sanchez V, Pol S, Bruyand M, Wittkop L, Zoulim F, Zucman-rossi J, L’hennaff M, Sizorn M, Cagnot C, the ANRS/AFEF Hepather study group. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. J Cannabis Res 2022;4:31. [DOI: 10.1186/s42238-022-00138-9] [Reference Citation Analysis]
29 Shukla TS, Gutlapalli SD, Farhat H, Irfan H, Muthiah K, Pallipamu N, Taheri S, Thiagaraj SS, Hamid P. The Usefulness of Combining Noninvasive Methods for Early Identification and Potential Prevention of Cystic Fibrosis-Associated Liver Disease. Cureus 2022;14:e32340. [PMID: 36628032 DOI: 10.7759/cureus.32340] [Reference Citation Analysis]
30 Choi AY, Chang KJ, Samarasena JB, Lee JG, Li X, Guo W, Chandan VS, Hu KQ. Endoscopic Ultrasound-Guided Porto-systemic Pressure Gradient Measurement Correlates with Histological Hepatic Fibrosis. Dig Dis Sci 2022;67:5685-92. [PMID: 35279787 DOI: 10.1007/s10620-022-07418-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Liu J, Tan L, Liu Z, Shi R. The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018. Ann Med 2022;54:2259-68. [PMID: 35975984 DOI: 10.1080/07853890.2022.2110277] [Reference Citation Analysis]
32 Lupușoru R, Sporea I, Rațiu I, Lungeanu D, Popescu A, Dănilă M, Mare R, Marc L, Lascău A, Moga TV, Bende F, Ghiuchici AM, Șirli R. Contrast-Enhanced Ultrasonography with Arrival Time Parametric Imaging as a Non-Invasive Diagnostic Tool for Liver Cirrhosis. Diagnostics (Basel) 2022;12. [PMID: 36553020 DOI: 10.3390/diagnostics12123013] [Reference Citation Analysis]
33 Lee S, Kim S, Lee S, Park H. Chronic viral hepatitis accelerates lung function decline in smokers. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00963-5] [Reference Citation Analysis]
34 Dolmazashvili E, Sharvadze L, Abutidze A, Chkhartishvili N, Todua M, Adamia E, Gabunia T, Shadaker S, Gvinjilia L, Arora S, Thornton K, Armstrong PA, Tsertsvadze T. Treatment of hepatitis C in primary health care in the country of Georgia. Clin Liver Dis (Hoboken) 2022;20:175-8. [PMID: 36447909 DOI: 10.1002/cld.1260] [Reference Citation Analysis]
35 Suan MAM, Chan HK, Sem X, Shilton S, Hassan MRA. Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection. Sci Rep 2022;12:20153. [PMID: 36418369 DOI: 10.1038/s41598-022-24612-9] [Reference Citation Analysis]
36 Naguib M, Abdel-razek W, Estaphan S, Abdelsameea E, Abdel-samiee M, Shafik NF. Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C. PLoS ONE 2022;17:e0276592. [DOI: 10.1371/journal.pone.0276592] [Reference Citation Analysis]
37 Iwadare T, Kimura T, Tanaka N, Yamazaki T, Wakabayashi SI, Okumura T, Kobayashi H, Yamashita Y, Pydi SP, Nakajima T, Iwaya M, Sugiura A, Joshita S, Uehara T, Umemura T. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients. Sci Rep 2022;12:18900. [PMID: 36344733 DOI: 10.1038/s41598-022-23357-9] [Reference Citation Analysis]
38 Iwadare T, Kimura T, Kunimoto H, Tanaka N, Wakabayashi S, Yamazaki T, Okumura T, Kobayashi H, Yamashita Y, Sugiura A, Joshita S, Umemura T. Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD. Biomedicines 2022;10:2806. [DOI: 10.3390/biomedicines10112806] [Reference Citation Analysis]
39 Watanabe Y, Osaki A, Waguri N, Tsuchiya A, Terai S. Prognostic study of acute-on-chronic liver failure patients: Usefulness of the fibrosis-4 index. Medicine 2022;101:e31328. [DOI: 10.1097/md.0000000000031328] [Reference Citation Analysis]
40 Inokuchi Y, Fujikawa H, Uematsu M, Takashina T. Transitional phase Gd-EOB-DTPA-enhanced MRI: Visual assessment of hepatic function and fibrosis based on uptake rate of Gd-EOB-DTPA. European Journal of Radiology 2022;156:110550. [DOI: 10.1016/j.ejrad.2022.110550] [Reference Citation Analysis]
41 Kramer JR, Cao Y, Li L, Smith D, Chhatwal J, El-Serag HB, Kanwal F. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol 2022;117:1834-44. [PMID: 36327437 DOI: 10.14309/ajg.0000000000001968] [Reference Citation Analysis]
42 Younossi ZM, Yu ML, El-Kassas M, Esmat G, Castellanos Fernández MI, Buti M, Papatheodoridis G, Yilmaz Y, Isakov V, Duseja A, Méndez-Sánchez N, Hamid S, Gordon SC, Romero-Gómez M, Chan WK, Ong JP, Younossi I, Lam B, Ziayee M, Nader F, Racila A, Henry L, Stepanova M; Global NASH Council™. Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry. J Viral Hepat 2022;29:1015-25. [PMID: 36036096 DOI: 10.1111/jvh.13741] [Reference Citation Analysis]
43 Yamataka K, Chu PS, Koda Y, Taniki N, Morikawa R, Yoshida A, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, Kanai T, Nakamoto N. Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts. PLoS One 2022;17:e0276925. [PMID: 36301899 DOI: 10.1371/journal.pone.0276925] [Reference Citation Analysis]
44 Ayyala D, Bottyan T, Tien C, Pimienta M, Yoo J, Stager K, Gonzalez JL, Stolz A, Dodge JL, Terrault NA, Han H. Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease. Hepatol Commun 2022;6:3433-42. [PMID: 36281979 DOI: 10.1002/hep4.2080] [Reference Citation Analysis]
45 Peschel G, Grimm J, Müller M, Höring M, Krautbauer S, Weigand K, Liebisch G, Buechler C. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection. Lipids Health Dis 2022;21:106. [PMID: 36280840 DOI: 10.1186/s12944-022-01715-w] [Reference Citation Analysis]
46 Hung WC, Tang WH, Yu TH, Wu CC, Wang CP, Lu YC, Wei CT, Chung FM, Lee YJ, Hsu CC. Low plasma growth/differentiation factor 1 levels are associated with liver fibrosis in patients with stable angina. J Clin Lab Anal 2022;:e24745. [PMID: 36268984 DOI: 10.1002/jcla.24745] [Reference Citation Analysis]
47 No JS, Buckholz A, Han C, Matthews S, Fortune B, Krisko T, Newberry C, Kumar S. Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease: An Opportunity for Intervention Within the Primary Care Setting. J Clin Gastroenterol 2022. [PMID: 36731002 DOI: 10.1097/MCG.0000000000001784] [Reference Citation Analysis]
48 Najashi KA, Najashi NA, Ahmed T, Abdelnaeem R, Alolit S, Zuaybir AA, Atiyah M, Trout AT, Alsaied T, Veldtman GR. The prognostic role of liver volumetry in Fontan patients. Cardiol Young 2022;:1-6. [PMID: 36258282 DOI: 10.1017/S1047951122002992] [Reference Citation Analysis]
49 Kwan AC, Sun N, Driver M, Botting P, Navarrette J, Ouyang D, Hussain SK, Noureddin M, Li D, Ebinger JE, Berman DS, Cheng S. Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study. Front Cardiovasc Med 2022;9:1009474. [DOI: 10.3389/fcvm.2022.1009474] [Reference Citation Analysis]
50 Li G, Wong GL, Yip TC, Tan Q, Lin H, Wilson JM, Bowsman LM, Haas JV, Chan AW, Leung HH, Zhang X, Tse Y, Shu SS, Chim AM, Chan HL, Yuen PC, Wong VW, Duffin KL, Chen Y. A Sequential Machine Learning Model for Identifying At-risk NASH by Combining Liver Stiffness Measurement and Protein Biomarkers.. [DOI: 10.21203/rs.3.rs-2118271/v1] [Reference Citation Analysis]
51 Huynh T, Ma S, Hu KQ. HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB-4 scores. Hepatol Commun 2022;6:3496-504. [PMID: 36221305 DOI: 10.1002/hep4.2098] [Reference Citation Analysis]
52 Park HJ, Seo KI, Lee SU, Han BH, Yun BC, Park ET, Lee J, Hwang H, Yoon M. Clinical usefulness of Mac-2 binding protein glycosylation isomer for diagnosing liver cirrhosis and significant fibrosis in patients with chronic liver disease: A retrospective single-center study. Medicine (Baltimore) 2022;101:e30489. [PMID: 36221351 DOI: 10.1097/MD.0000000000030489] [Reference Citation Analysis]
53 Forlano R, Stanic T, Jayawardana S, Mullish B, Yee M, Mossialos E, Goldin R, Petta S, Tsochatzis E, Thursz M, Manousou P. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.. [DOI: 10.21203/rs.3.rs-2135338/v1] [Reference Citation Analysis]
54 Kuma A, Mafune K, Uchino B, Ochiai Y, Miyamoto T, Kato A. Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men. Sci Rep 2022;12:16638. [PMID: 36198747 DOI: 10.1038/s41598-022-21039-0] [Reference Citation Analysis]
55 Kumada T, Toyoda H, Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouso K, Ishikawa T, Tamai T, Tada T, Tanaka J. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus. J Viral Hepat 2022;29:919-29. [PMID: 35790055 DOI: 10.1111/jvh.13728] [Reference Citation Analysis]
56 Toyoda H, Johnson PJ. The ALBI score: From liver function in patients with HCC to a general measure of liver function. JHEP Rep 2022;4:100557. [PMID: 36124124 DOI: 10.1016/j.jhepr.2022.100557] [Reference Citation Analysis]
57 Hampton JS, Koo S, Dobson C, Stewart CJ, Neilson LJ, Montague K, Mitra S, Whelpton J, Addison C, Kelly P, Rushton S, Hull MA, Sharp L, Rees CJ. The COLO-COHORT (Colorectal Cancer Cohort) study: Protocol for a multi-centre, observational research study and development of a consent-for-contact research platform. Colorectal Dis 2022;24:1216-26. [PMID: 35470953 DOI: 10.1111/codi.16160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Sato K, Inoue J, Akahane T, Kobayashi T, Sato S, Kisara N, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Masamune A. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. Medicine (Baltimore) 2022;101:e30630. [PMID: 36181074 DOI: 10.1097/MD.0000000000030630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Gunsaulus M, Wang L, Haack L, Christopher A, Feingold B, Squires J, Horslen S, Hoskoppal A, Rose-felker K, West S, Trucco S, Squires J, Olivieri L, Kreutzer J, Goldstein B, Alsaied T. Cardiac MRI Derived Inferior Vena Cava Cross-Sectional Area Correlates with Measures of Fontan Associated Liver Disease.. [DOI: 10.21203/rs.3.rs-2102272/v1] [Reference Citation Analysis]
60 Scutt P, Ban L, Card T, Crooks CJ, Guha N, West J, Morling JR. Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016. BMJ Open 2022;12:e058967. [PMID: 36167394 DOI: 10.1136/bmjopen-2021-058967] [Reference Citation Analysis]
61 Padeniya P, Ediriweera DS, De Silva AP, Niriella MA, Premawardhena A. Using FIB-4 score as a screening tool in the assessment of significant liver fibrosis (F2) in patients with transfusion-dependent beta thalassaemia: a cross-sectional study. BMJ Open 2022;12:e061156. [PMID: 36167380 DOI: 10.1136/bmjopen-2022-061156] [Reference Citation Analysis]
62 Parikh NS, Kamel H, Zhang C, Gupta A, Cohen DE, de Leon MJ, Gottesman RF, Iadecola C. Association of liver fibrosis with cognitive test performance and brain imaging parameters in the UK Biobank study. Alzheimers Dement 2022. [PMID: 36149265 DOI: 10.1002/alz.12795] [Reference Citation Analysis]
63 Hoyt JE, Teja N, Jiang T, Rozema L, Gui J, Watts BV, Shiner B, Gradus JL. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD. J Dual Diagn 2022;:1-14. [PMID: 36151743 DOI: 10.1080/15504263.2022.2123119] [Reference Citation Analysis]
64 Cai Y, Xue S, Li J, Xiao H, Lan T, Wu H. A novel nutritional score based on serum triglyceride and protein levels predicts outcomes of intrahepatic cholangiocarcinoma after curative hepatectomy: A multi-center study of 631 patients. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.964591] [Reference Citation Analysis]
65 Liu C, Kao J. Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection. Diagnostics 2022;12:2282. [DOI: 10.3390/diagnostics12102282] [Reference Citation Analysis]
66 Beiser ME, Shaw LC, Wilson GA, Muse KO, Shores SK, Baggett TP. Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014-2020. J Gen Intern Med 2022. [PMID: 36127534 DOI: 10.1007/s11606-022-07778-w] [Reference Citation Analysis]
67 Valdez KE, Javanbakht M, Keith K, Archer R, Deng JZ, Marx SE, Kuznetsova A, Dylla DE, Klausner JD. Healthcare resource utilization in Hepatitis C-infected patients completing eight versus twelve weeks of treatment: A retrospective cohort study. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.988971] [Reference Citation Analysis]
68 Pinto L, Balbi E, Halpern M, Carius L, Roma J, Cardoso SW, Grinsztejn B, Veloso VG, Pacheco L, Perazzo H. Effectiveness of Direct-acting Agents After Liver Transplantation and Regression of Biomarkers Post-HCV Treatment: A Real-life Study in Rio de Janeiro. Arch Med Res 2022:S0188-4409(22)00104-7. [PMID: 36114037 DOI: 10.1016/j.arcmed.2022.09.001] [Reference Citation Analysis]
69 Brozzetti S, D’alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. Cancers 2022;14:4422. [DOI: 10.3390/cancers14184422] [Reference Citation Analysis]
70 Cefalù AB, D'Erasmo L, Iannuzzo G, Noto D, Giammanco A, Montali A, Zambon A, Forte F, Suppressa P, Giannini S, Barbagallo CM, Ganci A, Nardi E, Vernuccio F, Caldarella R, Ciaccio M, Arca M, Averna M. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis 2022;359:13-9. [PMID: 36152419 DOI: 10.1016/j.atherosclerosis.2022.08.017] [Reference Citation Analysis]
71 Kawai S, Yamakage H, Kotani K, Noda M, Satoh-Asahara N, Hashimoto K. Analysis of time-dependent changes in the FIB4 index in patients with obesity receiving weight reduction therapy. Sci Rep 2022;12:15219. [PMID: 36075942 DOI: 10.1038/s41598-022-19420-0] [Reference Citation Analysis]
72 Shibata Y, Fukuda T, Nobeyama Y, Asahina A. Evaluation of nonalcoholic fatty liver disease in Japanese patients with psoriasis: Chest CT imaging for screening purposes. J Dermatol 2022. [PMID: 36074651 DOI: 10.1111/1346-8138.16564] [Reference Citation Analysis]
73 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2022;20:2041-2049.e5. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
74 Grigoras ML, Citu IM, Citu C, Chiriac VD, Gorun F, Levai MC, Manolescu D, Rosca O, Bratosin F, Gurumurthy S, Wulandari PH, Cretu OM. Evaluation of FIB-4, NFS, APRI and Liver Function Tests as Predictors for SARS-CoV-2 Infection in the Elderly Population: A Matched Case-Control Analysis. JCM 2022;11:5149. [DOI: 10.3390/jcm11175149] [Reference Citation Analysis]
75 Kablawi D, Alhinai A, Wong P, Deschenes M, Sebastiani G, Benmassaoud A. Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection. HIV Med 2022. [PMID: 36042533 DOI: 10.1111/hiv.13390] [Reference Citation Analysis]
76 Höring M, Peschel G, Grimm J, Krautbauer S, Müller M, Weigand K, Liebisch G, Buechler C. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection. IJMS 2022;23:9806. [DOI: 10.3390/ijms23179806] [Reference Citation Analysis]
77 Hattori N, Ikeda H, Watanabe T, Satta Y, Ehira T, Suzuki T, Kiyokawa H, Nakahara K, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Suzuki M, Itoh F, Tateishi K. Risk factors for liver‐related mortality of patients with hepatitis C virus after sustained virologic response to direct‐acting antiviral agents. JGH Open 2022. [DOI: 10.1002/jgh3.12805] [Reference Citation Analysis]
78 Shiner B, Huybrechts K, Gui J, Rozema L, Forehand J, Watts BV, Jiang T, Hoyt JE, Esteves J, Schnurr PP, Ray K, Gradus JL. Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection. Am J Epidemiol 2022;191:1614-25. [PMID: 35689641 DOI: 10.1093/aje/kwac104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Xu W, Li B, Yang Z, Li J, Liu F, Liu Y. Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study. J Hepatocell Carcinoma 2022;9:751-81. [PMID: 35983561 DOI: 10.2147/JHC.S372577] [Reference Citation Analysis]
80 Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. World J Gastroenterol 2022; 28(30): 4182-4200 [DOI: 10.3748/wjg.v28.i30.4182] [Reference Citation Analysis]
81 Yugawa K, Maeda T, Nagata S, Shiraishi J, Sakai A, Yamaguchi S, Konishi K, Hashimoto K. Impact of aspartate aminotransferase-to-platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcninoma. World J Surg Oncol 2022;20:248. [PMID: 35918753 DOI: 10.1186/s12957-022-02714-y] [Reference Citation Analysis]
82 Kumada T, Ogawa S, Goto T, Toyoda H, Yasuda S, Ito T, Yasuda E, Akita T, Tanaka J. Intra-individual Comparisons of the Ultrasound-Guided Attenuation Parameter and the Magnetic Resonance Imaging-Based Proton Density Fat Fraction Using Bias and Precision Statistics. Ultrasound Med Biol 2022;48:1537-46. [PMID: 35613974 DOI: 10.1016/j.ultrasmedbio.2022.03.019] [Reference Citation Analysis]
83 Pohl R, Eichelberger L, Feder S, Haberl EM, Rein-Fischboeck L, McMullen N, Sinal CJ, Bruckmann A, Weiss TS, Beck M, Höring M, Krautbauer S, Liebisch G, Wiest R, Wanninger J, Buechler C. Hepatocyte expressed chemerin-156 does not protect from experimental non-alcoholic steatohepatitis. Mol Cell Biochem 2022;477:2059-71. [PMID: 35449483 DOI: 10.1007/s11010-022-04430-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Lee J, Kwon Y, Park K, Lee HS, Park H, Han JH, Ahn SB. Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:3039. [DOI: 10.3390/nu14153039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
85 Liu H, Zhang Q, Gao F, Yu H, Jiang Y, Wang X. Platelet Count/Spleen Thickness Ratio and the Risk of Variceal Bleeding in Cirrhosis With Esophagogastric Varices. Front Med 2022;9. [DOI: 10.3389/fmed.2022.870351] [Reference Citation Analysis]
86 Nguyen HD, Kim MS. Cadmium, lead, and mercury mixtures interact with non-alcoholic fatty liver diseases. Environ Pollut 2022;309:119780. [PMID: 35841990 DOI: 10.1016/j.envpol.2022.119780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
87 Iwamoto K, Eriksson T. Predicting protease networks through human genetics.. [DOI: 10.1101/2022.06.30.498364] [Reference Citation Analysis]
88 Arai T, Atsukawa M, Tsubota A, Ono H, Kawano T, Yoshida Y, Okubo T, Hayama K, Nakagawa‐iwashita A, Itokawa N, Kondo C, Nagao M, Iwakiri K. Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. JGH Open 2022;6:503-511. [DOI: 10.1002/jgh3.12780] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Jagannathan R, Fiorentino TV, Marini MA, Sesti G, Bergman M. One-hour post-load glucose is associated with severity of hepatic fibrosis Risk. Diabetes Res Clin Pract 2022;189:109977. [PMID: 35772586 DOI: 10.1016/j.diabres.2022.109977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Rosa L, Vincenzo M, Annalisa C, Federica I, Giordano S, Giada P, Marco P, Irene M, Beatrice M, Elisa F, Matteo C, Alessandra B, Luca V, Flora P, Nicola M, Marina B, Ludovica FA. Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. Intern Emerg Med 2022. [PMID: 35754075 DOI: 10.1007/s11739-022-03000-1] [Reference Citation Analysis]
91 Egbe AC, Miranda WR, Jain CC, Kamath PS, Katta RR, Andi K, Goda AY, Connolly HM. Improvement in hepatic and renal function following isolated heart transplant in adults with congenital heart disease. Int J Cardiol 2022:S0167-5273(22)00924-X. [PMID: 35716930 DOI: 10.1016/j.ijcard.2022.06.024] [Reference Citation Analysis]
92 Lucijanic M, Madir A, Grgurevic I, Derek L, Unic A, Mustapic S, Zelenika M, Bokun T, Pastrovic F, Podrug K. Use of biochemical parameters for non-invasive screening of oesophageal varices in comparison to elastography-based approach in patients with compensated advanced chronic liver disease. Biochem med (Online) 2022;32:280-290. [DOI: 10.11613/bm.2022.020712] [Reference Citation Analysis]
93 Nguyen HD, Kim MS. Effects of chemical mixtures on liver function biomarkers in the Korean adult population: thresholds and molecular mechanisms for non-alcoholic fatty liver disease involved. Environ Sci Pollut Res Int 2022. [PMID: 35696061 DOI: 10.1007/s11356-022-21090-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Niu L, Thiele M, Geyer PE, Rasmussen DN, Webel HE, Santos A, Gupta R, Meier F, Strauss M, Kjaergaard M, Lindvig K, Jacobsen S, Rasmussen S, Hansen T, Krag A, Mann M. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med 2022. [PMID: 35654907 DOI: 10.1038/s41591-022-01850-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
95 Li T, Wang P, Gong X, Chong W, Hai Y, You C, Kang J, Fang F, Zhang Y. Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage. Front Neurol 2022;13:850405. [DOI: 10.3389/fneur.2022.850405] [Reference Citation Analysis]
96 Kamal A, Matta C, Mohsin HA, Elhadidi AS, Ghazy RM, Omar HH, Tahoun M, Mohamed NA. ASSESSING PREDICTORS OF DIRECTLY ACTING ANTIVIRALS’ FAILURE AS A FURTHER STEP TOWARDS MORE EFFICIENT HCV ELIMINATION PROGRAMS: IL28B (IFNL4) GENE POLYMORPHISM HAS NO ROLE WHILE HIGHER ESTIMATED CREATININE CLEARANCE IS A FORGOTTEN FACTOR. Arq Gastroenterol 2022;59:177-183. [DOI: 10.1590/s0004-2803.202202000-33] [Reference Citation Analysis]
97 Shimagaki T, Sugimachi K, Mano Y, Onishi E, Iguchi T, Uehara H, Sugiyama M, Yamamoto M, Morita M, Toh Y. Simple systemic index associated with oxaliplatin‐induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12580] [Reference Citation Analysis]
98 Lee KS, Cho Y, Kim H, Hwang H, Cho JW, Lee Y, Lee S. Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1216. [DOI: 10.3390/biomedicines10061216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Sagaram M, Parthasarathy R, Condon SL, Closson CF, Kong M, Schwandt ML, Jophlin LL, Feng W, Barve AJ, Vatsalya V. Theragnostic Efficacy of K18 Response in Alcohol Use Disorder with Clinically Significant Fibrosis Using Gut-Liver Axis. Int J Mol Sci 2022;23:5852. [PMID: 35628661 DOI: 10.3390/ijms23105852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Fujii H, Kimura H, Hasebe C, Akahane T, Satou T, Kusakabe A, Kojima Y, Kondo M, Marusawa H, Kobashi H, Tsuji K, Ogawa C, Uchida Y, Joko K, Mitsuda A, Kurosaki M, Izumi N. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. [DOI: 10.1002/jgh3.12749] [Reference Citation Analysis]
101 Melania G, Luisella V, Salvina DP, Francesca G, Amedea Silvia T, Fabrizia B, Maristella M, Filomena N, Kyriazoula C, Vassalle C. Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity. Eat Weight Disord 2022. [PMID: 35527326 DOI: 10.1007/s40519-022-01400-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Madebo T, Bemanian M, Vold JH, Chowdhury R, Aas CF, Druckrey-fiskaaen KT, Johansson KA, Fadnes LT. Vitamin B12 Levels, Substance Use Patterns and Clinical Characteristics among People with Severe Substance Use Disorders: A Cohort Study from Western Norway. Nutrients 2022;14:1941. [DOI: 10.3390/nu14091941] [Reference Citation Analysis]
103 Branković M, Jovanović I, Dukić M, Radonjić T, Oprić S, Klašnja S, Zdravković M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;23:5146. [PMID: 35563534 DOI: 10.3390/ijms23095146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
104 Somers N, Vandekerckhove E, Geerts A, Degroote H, Lefere S, Devisscher L, Meuris L, Callewaert N, Van Vlierberghe H, Verhelst X. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. Acta Clin Belg 2022;:1-7. [PMID: 35505274 DOI: 10.1080/17843286.2022.2072110] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Song K, Lee HW, Choi HS, Park G, Lee HS, Kim SJ, Lee M, Suh J, Kwon A, Kim H, Chae HW. Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth. Biology 2022;11:685. [DOI: 10.3390/biology11050685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Keimburg SA, Theysohn J, Buechter M, Rashidi-alavijeh J, Willuweit K, Schneider H, Wetter A, Maasoumy B, Lange C, Wedemeyer H, Markova AA. FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. Biomedicines 2022;10:1018. [DOI: 10.3390/biomedicines10051018] [Reference Citation Analysis]
107 Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
108 Kwon Y, Kim ES, Choe YH, Kim MJ. Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children. Front Pediatr 2022;10:846273. [PMID: 35444966 DOI: 10.3389/fped.2022.846273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Niitsuma H, Masamune A; THERME Study Group. Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. JCM 2022;11:2354. [DOI: 10.3390/jcm11092354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Saranskaya Y, Kiseleva L, Il'mukhina L. OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT. Ulyanovsk Medico-biological Journal 2022. [DOI: 10.34014/2227-1848-2022-1-39-48] [Reference Citation Analysis]
111 Erdal H, Bakir A, Güney M, Günal A, Gülşen M. Relationship between Histopathological Stages of Liver and Albumin-Bilirubin Score in Hepatitis B Infection. Düzce Tıp Fakültesi Dergisi 2022. [DOI: 10.18678/dtfd.1055076] [Reference Citation Analysis]
112 Liu T, Huang C, Tsai P, Yeh M, Jang T, Huang J, Dai C, Yu M, Chuang W. The compound annual growth rate of the fibrosis‐4 index in chronic hepatitis B patients. The Kaohsiung J of Med Scie. [DOI: 10.1002/kjm2.12543] [Reference Citation Analysis]
113 Chang L, Chang H, Chen P, Chen C, Tsai K, Yean K, Yang H, Chen T, Yu P, Chou C, Chen S. Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan. Medicina 2022;58:521. [DOI: 10.3390/medicina58040521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Takakusagi S, Saito N, Ueno T, Hatanaka T, Namikawa M, Tojima H, Takizawa D, Naganuma A, Kosone T, Arai H, Sato K, Kakizaki S, Takagi H, Uraoka T. Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals. DEN Open 2022;2. [DOI: 10.1002/deo2.11] [Reference Citation Analysis]
115 Yodoshi T, Orkin S, Trout AT, Arce-Clachar AC, Bramlage K, Liu C, Fei L, Dillman JR, Xanthakos SA, Mouzaki M. Non-Invasive Approaches to Estimate Liver Steatosis and Stiffness in Children With Non-Alcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2022;74:495-502. [PMID: 34908012 DOI: 10.1097/MPG.0000000000003371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Fujimori N, Kimura T, Tanaka N, Yamazaki T, Okumura T, Kobayashi H, Wakabayashi SI, Yamashita Y, Sugiura A, Pham J, Pydi SP, Sano K, Joshita S, Umemura T. 2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. Hepatol Res 2022;52:352-63. [PMID: 35040549 DOI: 10.1111/hepr.13745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Wang J, Tang S, Mao Y, Wu J, Xu S, Yue Q, Chen J, He J, Yin Y. Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker. Hepatol Int. [DOI: 10.1007/s12072-022-10326-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
118 Shearer JE, Jones R, Parker R, Ferguson J, Rowe IA. The Natural History of Advanced Chronic Liver Disease Defined by Transient Elastography. Clinical Gastroenterology and Hepatology 2022. [DOI: 10.1016/j.cgh.2022.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Staging Fibrosis in Chronic Viral Hepatitis. Viruses 2022;14:660. [PMID: 35458391 DOI: 10.3390/v14040660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Tana MM, Klepper A, Lyden A, Pisco AO, Phelps M, Mcgee B, Green K, Feng S, Derisi J, Crawford ED, Lammert CS. Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management. PLoS ONE 2022;17:e0264307. [DOI: 10.1371/journal.pone.0264307] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
121 Minamikawa T, Hase E, Ichimura-shimizu M, Morimoto Y, Suzuki A, Yasui T, Nakamura S, Tsutsui A, Takaguchi K, Tsuneyama K. Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. IJMS 2022;23:3357. [DOI: 10.3390/ijms23063357] [Reference Citation Analysis]
122 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Toyota J. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. Ann Hepatol 2022;27:100566. [PMID: 34688887 DOI: 10.1016/j.aohep.2021.100566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Yu Q, Huang Y, Li X, Pavlides M, Liu D, Luo H, Ding H, An W, Liu F, Zuo C, Lu C, Tang T, Wang Y, Huang S, Liu C, Zheng T, Kang N, Liu C, Wang J, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Fang Q, Fu CC, Zhang R, Wang C, Wei J, Tian J, Örmeci N, Ellik Z, Asiller ÖÖ, Ju S, Qi X. An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension. Cell Rep Med 2022;3:100563. [PMID: 35492878 DOI: 10.1016/j.xcrm.2022.100563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Gad AI, Abdel-ghani HA, Barakat AAA. Effect of Ramadan fasting on hepatic steatosis as quantified by controlled attenuation parameter (CAP): a prospective observational study. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00187-y] [Reference Citation Analysis]
125 Shirakabe A, Okazaki H, Matsushita M, Shibata Y, Shigihara S, Nishigoori S, Sawatani T, Sasamoto N, Kiuchi K, Atsukawa M, Itokawa N, Arai T, Kobayashi N, Asai K. Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure. ESC Heart Fail 2022. [PMID: 35289118 DOI: 10.1002/ehf2.13878] [Reference Citation Analysis]
126 Hale AJ, Mathur S, Dejace J, Lidofsky SD. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont. Public Health Rep 2022;:333549221077070. [PMID: 35264027 DOI: 10.1177/00333549221077070] [Reference Citation Analysis]
127 Pérez-Is L, Collazos J, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, Fonseca-González GJ, Melón S, Valle-Garay E, Asensi V. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci Rep 2022;12:3828. [PMID: 35264591 DOI: 10.1038/s41598-022-07548-y] [Reference Citation Analysis]
128 Naeem M, Markus MRP, Mousa M, Schipf S, Dörr M, Steveling A, Aghdassi A, Kühn JP, Kromrey ML, Nauck M, Targher G, Völzke H, Ittermann T. Associations of liver volume and other markers of hepatic steatosis with all-cause mortality in the general population. Liver Int 2022;42:575-84. [PMID: 34894052 DOI: 10.1111/liv.15133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
129 Alswat K, Al-Sohaibani F, Khathlan A, Bashmail A, Alanazi M, Kurdi A, Almakadma AH, Al-Hamoudi W. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. Ann Saudi Med 2022;42:89-95. [PMID: 35380056 DOI: 10.5144/0256-4947.2022.89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lin M, Dai C, Huang C, Yeh M, Liu Y, Hsu P, Wei Y, Lee P, Huang C, Liang P, Hsieh M, Hsieh M, Jang T, Lin Z, Huang J, Yu M, Chuang W. Itemization difference of patient-reported outcome in patients with chronic liver disease. PLoS ONE 2022;17:e0264348. [DOI: 10.1371/journal.pone.0264348] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Weinstein G, O'Donnell A, Davis-Plourde K, Zelber-Sagi S, Ghosh S, DeCarli CS, Thibault EG, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. J Alzheimers Dis 2022. [PMID: 35213373 DOI: 10.3233/JAD-215409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
132 Sebastiani G, Milic J, Cervo A, Saeed S, Krahn T, Kablawi D, Al Hinai AS, Lebouché B, Wong P, Deschenes M, Gioè C, Cascio A, Mazzola G, Guaraldi G. Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. JPM 2022;12:282. [DOI: 10.3390/jpm12020282] [Reference Citation Analysis]
133 Barré T, Fontaine H, Pol S, Ramier C, Di Beo V, Protopopescu C, Marcellin F, Bureau M, Bourlière M, Dorival C, Petrov-sanchez V, Asselah T, Delarocque-astagneau E, Larrey D, Duclos-vallée J, Carrat F, Carrieri P; on behalf of the ANRS/AFEF Hepather Study Group. Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort). Antioxidants 2022;11:379. [DOI: 10.3390/antiox11020379] [Reference Citation Analysis]
134 Šmíd V, Dvořák K, Šedivý P, Kosek V, Leníček M, Dezortová M, Hajšlová J, Hájek M, Vítek L, Bechyňská K, Brůha R. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun 2022. [PMID: 35147302 DOI: 10.1002/hep4.1906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
135 Parikh NS, Kamel H, Zhang C, Kumar S, Rosenblatt R, Spincemaille P, Gupta A, Cohen DE, de Leon MJ, Gottesman RF, Iadecola C. Association between Liver Fibrosis and Incident Dementia in the UK Biobank Study.. [DOI: 10.1101/2022.02.09.22270729] [Reference Citation Analysis]
136 Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J. Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection. Eur Radiol 2022. [PMID: 35142900 DOI: 10.1007/s00330-022-08570-4] [Reference Citation Analysis]
137 Mikolasevic I, Domislovic V, Krznaric-zrnic I, Krznaric Z, Virovic-jukic L, Stojsavljevic S, Grgurevic I, Milic S, Vukoja I, Puz P, Aralica M, Hauser G. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina 2022;58:252. [DOI: 10.3390/medicina58020252] [Reference Citation Analysis]
138 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
139 Maeda D, Kanzaki Y, Sakane K, Tsuda K, Akamatsu K, Hourai R, Okuno T, Tokura D, Nakayama S, Hasegawa H, Morita H, Ito T, Hoshiga M. Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with acute heart failure. ESC Heart Fail 2022. [PMID: 35119215 DOI: 10.1002/ehf2.13829] [Reference Citation Analysis]
140 Wu H, Jeng W, Pan M, Hsieh Y, Lu S, Chen C, Yang H. Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection. JHEP Reports 2022;4:100410. [DOI: 10.1016/j.jhepr.2021.100410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther 2022;55:422-33. [PMID: 34812502 DOI: 10.1111/apt.16691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
142 Glisic T, Stojkovic Lalosevic M, Milovanovic T, Rankovic I, Stojanovic M, Toplicanin A, Aleksic M, Milivojevic V, Martinov Nestorov J, Lolic I, Popovic DD. Diagnostic Value of Non-invasive Scoring Systems in the Prediction of Esophageal Varices in Patients with Liver Cirrhosis—Single Center Experience. Medicina 2022;58:158. [DOI: 10.3390/medicina58020158] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, Koch D, Gebregziabher M. The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. J GEN INTERN MED. [DOI: 10.1007/s11606-021-07341-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Bernstein D, Kovalic AJ. Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. Metabol Open 2022;13:100158. [PMID: 35036892 DOI: 10.1016/j.metop.2021.100158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
145 Chen Q, Gao M, Yang H, Mei L, Zhong R, Han P, Liu P, Zhao L, Wang J, Li J. Serum ferritin levels are associated with advanced liver fibrosis in treatment-naive autoimmune hepatitis. BMC Gastroenterol 2022;22:23. [PMID: 35034629 DOI: 10.1186/s12876-022-02098-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
146 Padeniya P, Ediriweera D, De Silva A, Niriella M, Premawardhena A. Using FIB-4 score as a screening tool in the assessment of significant liver fibrosis (F2) in patients with transfusion dependent beta thalassaemia: a cross sectional study.. [DOI: 10.1101/2022.01.15.22269369] [Reference Citation Analysis]
147 Miyasaka A, Yoshida Y, Murakami A, Hoshino T, Sawara K, Numao H, Takikawa Y. Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection. Health Sci Rep 2022;5:e458. [PMID: 35024454 DOI: 10.1002/hsr2.458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Abd-Elsalam SM, Ezz MM, Gamalel-Din S, Esmat G, Elakel W, ElHefnawi M. Derivation of "Egyptian varices prediction (EVP) index": A novel noninvasive index for diagnosing esophageal varices in HCV Patients. J Adv Res 2022;35:87-97. [PMID: 35024195 DOI: 10.1016/j.jare.2021.02.005] [Reference Citation Analysis]
149 Zuluaga P, Teniente-Serra A, Fuster D, Quirant-Sánchez B, Hernandez-Rubio A, Martínez-Cáceres E, Muga R. Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change. J Clin Med 2022;11:305. [PMID: 35054000 DOI: 10.3390/jcm11020305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
150 Unsal İO, Calapkulu M, Sencar ME, Cakal B, Ozbek M. Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. Sci Rep 2022;12:283. [PMID: 34997159 DOI: 10.1038/s41598-021-04361-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
151 Cao J, Qiu W, Yu Y, Li N, Wu H, Chen Z. The association between serum albumin and depression in chronic liver disease may differ by liver histology. BMC Psychiatry 2022;22:5. [PMID: 34983435 DOI: 10.1186/s12888-021-03647-8] [Reference Citation Analysis]
152 Kim KH, Kim Y, Seo KI, Seo KW. Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective. Ann Surg Treat Res 2022;102:353. [DOI: 10.4174/astr.2022.102.6.353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res 2022;52:81-92. [PMID: 34665918 DOI: 10.1111/hepr.13723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
154 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2022;29:35-42. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
155 Romero S, Holmes JA. Editorial: hepatocellular carcinoma risk prediction models following DAA-mediated SVR-more evidence needed. Aliment Pharmacol Ther 2022;55:135-6. [PMID: 34907553 DOI: 10.1111/apt.16695] [Reference Citation Analysis]
156 Chhabra S, Singh SP, Singh A, Mehta V, Kaur A, Bansal N, Sood A. Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol 2022;12:409-16. [PMID: 35535092 DOI: 10.1016/j.jceh.2021.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
157 Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2022;29:52-9. [PMID: 34695288 DOI: 10.1111/jvh.13627] [Reference Citation Analysis]
158 Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.01.006] [Reference Citation Analysis]
159 Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 2021;16:e0261878. [PMID: 34962955 DOI: 10.1371/journal.pone.0261878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Liu Y, Tang T, Örmeci N, Huang Y, Wang J, Li X, Li Z, An W, Liu D, Zhang C, Liu C, Liu J, Liu C, Wang G, Mosconi C, Cappelli A, Bruno A, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Li L, Zhang H, Kang N, Xu D, He R, Wang Y, Bu Y, Gu Y, Ju S, Golfieri R, Qi X. Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. J Clin Transl Hepatol 2021;9:818-27. [PMID: 34966645 DOI: 10.14218/JCTH.2021.00177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Liao X, Zhao S, Yin J, Liu L, Liang J, Jiang Y, Yu N, Fan R, Zhong C. Sexual Dysfunction in Patients with Chronic Hepatitis B: Prevalence and Risk Factors. J Sex Med 2021:S1743-6095(21)00792-X. [PMID: 34969615 DOI: 10.1016/j.jsxm.2021.11.016] [Reference Citation Analysis]
162 Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. Potential role of noninvasive biomarkers during liver fibrosis. World J Hepatol 2021; 13(12): 1919-1935 [DOI: 10.4254/wjh.v13.i12.1919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Rossetti B, Borgo V, Emiliozzi A, Colaneri M, Zanelli G, d’Alessandro M, Motta D, Maiocchi L, Montagnani F, Moioli MC, Baiguera C, Sambo M, Pieri TC, Valsecchi P, Bruno R, Puoti M, Fabbiani M. Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. Diagnostics 2021;12:14. [DOI: 10.3390/diagnostics12010014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, Moon JH, Choi SH, Jang HC. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep 2021;11:24372. [PMID: 34934162 DOI: 10.1038/s41598-021-03870-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
165 Yang R, Gui X, Ke H, Xiong Y, Gao S. Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection. AIDS Res Ther 2021;18:98. [PMID: 34924016 DOI: 10.1186/s12981-021-00419-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
166 Ikeda S, Sugihara T, Kihara T, Matsuki Y, Nagahara T, Takata T, Kitao S, Okura T, Yamamoto K, Isomoto H. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. Diagnostics (Basel) 2021;11:2316. [PMID: 34943553 DOI: 10.3390/diagnostics11122316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Miyasaka A, Yoshida Y, Suzuki A, Sawara K, Takikawa Y. A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination. Int J Gen Med 2021;14:8935-43. [PMID: 34866934 DOI: 10.2147/IJGM.S344492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021;21:453. [PMID: 34861841 DOI: 10.1186/s12876-021-02038-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Meren E, Sawai Y, Fukuda K, Igura T, Kogita S, Yukimura Y, Seki Y, Fujita N, Oshita M, Imai Y. Risk stratification of hepatocellular carcinoma in patients with chronic liver disease by combining gadolinium‐ethoxybenzyl diethylenetriamine‐pentaacetic acid–enhanced magnetic resonance imaging and magnetic resonance elastography. GastroHep 2021;3:435-442. [DOI: 10.1002/ygh2.495] [Reference Citation Analysis]
170 Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J. Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. Eur J Gastroenterol Hepatol 2021;33:e513-21. [PMID: 33852513 DOI: 10.1097/MEG.0000000000002139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Yilmaz B, Kayadibi H, Yeniova AO, Koseoglu H, Simsek Z. The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2021;33:e290-6. [PMID: 33405426 DOI: 10.1097/MEG.0000000000002038] [Reference Citation Analysis]
172 Debroy P, Nagraj S, Chamorro-pareja N, Castro N, de Leon A, Guerson-gil A, Quintero O, Laniado I, Kladas M, Desai D, Mathias P, Leider J, Kishore P, Palaiodimos L, Kotler DP. Assessment of the Association of HIV Infection with Hepatic Steatosis or Fibrosis: a Cross-sectional Case–Control Study. SN Compr Clin Med 2021;3:2504-2510. [DOI: 10.1007/s42399-021-01054-4] [Reference Citation Analysis]
173 Pestana NF, Equi CMA, Gomes CP, Cardoso AC, Zumack JP, Villela-Nogueira CA, Perez RM. Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients. Eur J Gastroenterol Hepatol 2021;33:e260-5. [PMID: 33405422 DOI: 10.1097/MEG.0000000000002031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Nah EH, Cho S, Park H, Noh D, Kwon E, Cho HI. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. PLoS One 2021;16:e0260477. [PMID: 34818372 DOI: 10.1371/journal.pone.0260477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Kim HM, Lee YH. The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008-2011). Endocrinol Metab (Seoul) 2021. [PMID: 34809412 DOI: 10.3803/EnM.2021.1087] [Reference Citation Analysis]
176 Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, Eisenberg D, Azagury DE, Ikramuddin S. ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis. Surg Obes Relat Dis 2021:S1550-7289(21)00548-7. [PMID: 34953742 DOI: 10.1016/j.soard.2021.11.015] [Reference Citation Analysis]
177 Lee JHM, Loo CH, Tan WC, Lee CK, Jamil A, Khor YH. Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients. Dermatol Ther 2021;:e15203. [PMID: 34779102 DOI: 10.1111/dth.15203] [Reference Citation Analysis]
178 Zhang X, Huang P, Wang X, Zhou K, Chen F, Zhou C, Yu L, Lu Q, Zhou J, Hu J, Wang Z. Development and validation of a non-invasive model for diagnosing HBV-related liver cirrhosis. Clin Chim Acta 2021;523:525-31. [PMID: 34748781 DOI: 10.1016/j.cca.2021.11.004] [Reference Citation Analysis]
179 Broquetas T, Herruzo-Pino P, Mariño Z, Naranjo D, Vergara M, Morillas RM, Forns X, Carrión JA. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. Liver Int 2021;41:2733-46. [PMID: 34525253 DOI: 10.1111/liv.15058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
180 Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther 2021;54:1340-9. [PMID: 34618934 DOI: 10.1111/apt.16632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
181 Kanki A, Maeba K, Sotozono H, Yasokawa K, Higaki A, Yamamoto A, Tamada T. Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers. Br J Radiol 2021;94:20210045. [PMID: 34586878 DOI: 10.1259/bjr.20210045] [Reference Citation Analysis]
182 Kamal A, Ramadan A, Sherief D, Hassan A, Nosair N, Mabrouk M, Habeeb E, Haydra T. Relation between levels of toll-like receptors 3 and 7 and clinical profile of Child-Pugh B cirrhotic patients. Clin Exp Hepatol 2021;7:293-6. [PMID: 34712831 DOI: 10.5114/ceh.2021.109336] [Reference Citation Analysis]
183 Emamaullee J, Khan S, Weaver C, Goldbeck C, Yanni G, Kohli R, Genyk Y, Zhou S, Shillingford N, Sullivan PM, Takao C, Detterich J, Kantor PF, Cleveland JD, Herrington C, Ram Kumar S, Starnes V, Badran S, Patel ND. Non-invasive biomarkers of Fontan-associated liver disease. JHEP Rep 2021;3:100362. [PMID: 34693238 DOI: 10.1016/j.jhepr.2021.100362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
184 Niezen S, Tapper EB, Trivedi H, Lai M, Curry MP, Mukamal KJ, Jiang ZG. Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults. Hepatol Commun 2021. [PMID: 34697916 DOI: 10.1002/hep4.1837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Hiraoka A, Onishi M, Koyama S, Kato M, Marui K, Murakami T, Onishi K, Adachi T, Matsuoka J, Ueki H, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Kuroda T, Iwasaki R, Suga Y, Miyata H, Ninomiya T, Hirooka M, Abe M, Matsuura B, Michitaka K, Hiasa Y. Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease. Intern Med 2021;60:3195-203. [PMID: 34657905 DOI: 10.2169/internalmedicine.7129-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Hanafy AS, Mohamed MS, Taleb MA, Mohammed HM, Ibrahim TMH, Saber S, Atia HA. Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00151-2] [Reference Citation Analysis]
187 Minemura M, Tajiri K, Hayashi Y, Takahashi N, Watanabe K, Hanaoka T, Araki Y, Takahashi K, Takahara T, Kojima S, Yasuda I. Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Intern Med 2021;60:3239-43. [PMID: 33896867 DOI: 10.2169/internalmedicine.7132-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Xu H, Li X, Wu Z, Zhao L, Shen J, Liu J, Qin J, Shen Y, Ke J, Wei Y, Li J, Gao Y. LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB. Front Mol Biosci 2021;8:749648. [PMID: 34631799 DOI: 10.3389/fmolb.2021.749648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease 2021;32:582-8. [PMID: 34631983 DOI: 10.1007/s13337-021-00712-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Martínez-Urbistondo D, de la Garza RG, Villares-Fernández P, Font C, Schellong S, López-Núñez JJ, Gil-Díaz A, Del Carmen Díaz-Pedroche M, Hirmerova J, Monreal M; RIETE Investigators. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Intern Emerg Med 2021. [PMID: 34626318 DOI: 10.1007/s11739-021-02858-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Isoura Y, Yamamoto A, Cho Y, Ehara E, Jogo A, Suzuki T, Amano-Teranishi Y, Kioka K, Hamazaki T, Murakami Y, Tokuhara D. Platelet count and abdominal dynamic CT are useful in predicting and screening for gastroesophageal varices after Fontan surgery. PLoS One 2021;16:e0257441. [PMID: 34618830 DOI: 10.1371/journal.pone.0257441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Naito S, Fujikawa T, Kouno N, Hasegawa S. Is laparoscopic liver resection safe for super-elderly patients (aged ≥80)? A propensity score-matched analysis. Asian J Endosc Surg 2021. [PMID: 34612004 DOI: 10.1111/ases.12994] [Reference Citation Analysis]
193 Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021;36:2943-51. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
194 Ruan D, Shi Y, Jin L, Yang Q, Yu W, Ren H, Zheng W, Chen Y, Zheng N, Zheng M. An ultrasound image-based deep multi-scale texture network for liver fibrosis grading in patients with chronic HBV infection. Liver Int 2021;41:2440-54. [PMID: 34219353 DOI: 10.1111/liv.14999] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
195 Sato S, Tsuzura H, Kita Y, Ikeda Y, Kabemura D, Sato S, Amano N, Yatagai N, Murata A, Shimada Y, Genda T. Post‐treatment serum Wisteria floribunda agglutinin‐positive mac‐2‐binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication. JGH Open 2021;5:1203-1209. [DOI: 10.1002/jgh3.12655] [Reference Citation Analysis]
196 Elbasiony M, Abed H, Alaskalany HM, Saleh A. Transient elastography and platelet count as noninvasive predictors of gastroesophageal varices in patients with compensated hepatitis C virus–related liver cirrhosis. Medical Journal Armed Forces India 2021. [DOI: 10.1016/j.mjafi.2021.08.008] [Reference Citation Analysis]
197 Varchetta S, Mele D, D'Ambrosio R, Perbellini R, Lombardi A, Rojas A, Paolucci S, Baldanti F, Oliviero B, Mantovani S, Tinelli C, De Silvestri A, Romero Gomez M, Lampertico P, Mondelli MU. A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. J Viral Hepat 2021;28:1443-51. [PMID: 34228858 DOI: 10.1111/jvh.13570] [Reference Citation Analysis]
198 Moini M, Onofrio F, Hansen BE, Adeyi O, Khalili K, Patel K. Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. Sci Rep 2021;11:19275. [PMID: 34588540 DOI: 10.1038/s41598-021-98776-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Raziky MESE, Zayed NA, Ibrahim YS, Elrashdy F, Shahin RMH, Hassany M, Serafy ME, Doss W, Uversky VN, Yosry A, Eldeen HG. Association Analysis of Genetic Variants of Sodium Taurocholate Co-Transporting Polypeptide NTCP Gene (SLC10A1) and HBV Infection Status in a Cohort of Egyptian Patients. Gastroenterology Insights 2021;12:384-93. [DOI: 10.3390/gastroent12040037] [Reference Citation Analysis]
200 Krasner YA, Osipenko MF, Litvinova NV, Bikbulatova EA, Holin SI, Klimotov VV. Non-alcoholic fatty liver disease - a look at diagnostic prospects. jour 2021. [DOI: 10.31146/1682-8658-ecg-191-7-62-67] [Reference Citation Analysis]
201 Lin JJ, Loucks CM, Trueman JN, Drögemöller BI, Wright GEB, Yoshida EM, Ford JA, Lee SS, Kim RB, Al-Judaibi B, Schwarz UI, Ramji A, Tam E, Ross CJ, Carleton BC. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Biomed Pharmacother 2021;143:112195. [PMID: 34562771 DOI: 10.1016/j.biopha.2021.112195] [Reference Citation Analysis]
202 Zelenika M, Lucijanic M, Bokun T, Bozin T, Barisic Jaman M, Tjesic Drinkovic I, Pastrovic F, Madir A, Luksic I, Piskac Zivkovic N, Luetic K, Krznaric Z, Ostojic R, Filipec Kanizaj T, Bogadi I, Virovic Jukic L, Kukla M, Grgurevic I. FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19. J Clin Med 2021;10:4355. [PMID: 34640373 DOI: 10.3390/jcm10194355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Zhao W, Xue N, Cui P, Liu L, Wang Y, Zhang X, Tang Y, Du H, Nan Y. Plasma YAP1 predicts esophageal varices and the risk of variceal bleeding in liver cirrhosis. Biomark Med 2021;15:1411-22. [PMID: 34533050 DOI: 10.2217/bmm-2020-0573] [Reference Citation Analysis]
204 Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, Fallowfield JA, Hayward C, Henderson NC, Joshi PK, Mills NL, Porteous DJ, Ramachandran P, Semple RK, Shaw CA, Sudlow CLM, Timmers PRHJ, Wilson JF, Wigmore SJ, Harrison EM, Spiliopoulou A. Genome-Wide Association Study of NAFLD Using Electronic Health Records. Hepatol Commun 2021. [PMID: 34535985 DOI: 10.1002/hep4.1805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
205 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
206 Sung MJ, Lim TS, Jeon MY, Lee HW, Kim BK, Kim DY, Ahn SH, Han KH, Park JY, Kim SU. Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. Gut Liver 2020;14:626-35. [PMID: 32135582 DOI: 10.5009/gnl19126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
207 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Huang CE, Chang JJ, Wu YY, Huang SH, Chen WM, Hsu CC, Lu CH, Hung CH, Shi CS, Lee KD, Chen CC, Chen MC. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J 2021:S2319-4170(21)00113-X. [PMID: 34508913 DOI: 10.1016/j.bj.2021.09.001] [Reference Citation Analysis]
209 Lee KJ, Moon JS, Kim NY, Ko JS. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children. Pediatr Obes 2021;:e12852. [PMID: 34490745 DOI: 10.1111/ijpo.12852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
210 Kawaguchi T, Ide T, Amano K, Arinaga-Hino T, Kuwahara R, Sano T, Miki S, Ono N, Torimura T. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol 2021;15:215. [PMID: 34476099 DOI: 10.3892/mco.2021.2377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
211 Tuzer C, Sertbas Y, Duman E, Komoglu S, Kan O, Ay S, Yigit A, Sertbas M, Okuroglu N, Ozen B, Dalbeler A, Ozdemir A. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus. Eur J Gastroenterol Hepatol 2021;33:1222-8. [PMID: 34397640 DOI: 10.1097/MEG.0000000000002189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Madsen BS, Thiele M, Detlefsen S, Kjaergaard M, Møller LS, Trebicka J, Nielsen MJ, Gudmann NS, Leeming DJ, Karsdal MA, Krag A; GALAXY consortium. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. Aliment Pharmacol Ther 2021;54:699-708. [PMID: 34251031 DOI: 10.1111/apt.16513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
213 Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, Tanaka J. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. J Viral Hepat 2021;28:1293-303. [PMID: 34185932 DOI: 10.1111/jvh.13562] [Reference Citation Analysis]
214 Przekop D, Klapaczynski J, Grytczuk A, Gruszewska E, Gietka A, Panasiuk A, Golaszewski S, Cylwik B, Chrostek L. Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C. J Clin Med 2021;10:3951. [PMID: 34501398 DOI: 10.3390/jcm10173951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. J Pers Med 2021;11:844. [PMID: 34575621 DOI: 10.3390/jpm11090844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
216 Li Z, Li S, Tao H, Zhan Y, Ni K, Gong J, Li G. Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer. World J Surg Oncol 2021;19:251. [PMID: 34446030 DOI: 10.1186/s12957-021-02369-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Yabe Y, Kim T, Oh S, Shida T, Oshida N, Hasegawa N, Okada K, Someya N, Mizokami Y, Shoda J. Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty Liver Disease Featuring Advanced Fibrosis. Int J Environ Res Public Health 2021;18:8918. [PMID: 34501508 DOI: 10.3390/ijerph18178918] [Reference Citation Analysis]
218 Kilany S, Ata L, Gomaa A, Sabry A, Nada A, Tharwa ES, Badra G, Abogabal A, Elwaraky M, Moaz E, Ezzat S, Elsharawy A, Waked I. Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. J Hepatocell Carcinoma 2021;8:925-35. [PMID: 34408991 DOI: 10.2147/JHC.S295330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Levy J, Bobak C, Azizgolshani N, Andersen M, Suriawinata A, Liu X, Lisovsky M, Ren B, Christensen B, Vaickus L, O’malley AJ. Bridge Category Models: Development of Bayesian Modelling Procedures to Account for Bridge Ordinal Ratings for Disease Staging.. [DOI: 10.1101/2021.08.17.456726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
220 Zhang H, Shi X, Wang L, Zeng Y, Kang X, Huang L. Performance of noninvasive tools for identification of minimal liver fibrosis in patients with hepatitis B virus infection. J Clin Lab Anal 2021;35:e23960. [PMID: 34403524 DOI: 10.1002/jcla.23960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
221 Hoshino Y, Sugihara T, Ikeda S, Matsuki Y, Nagahara T, Okano JI, Isomoto H. A vein-viewing application enabled detecting abdominal wall varices related to the presence of non-treated gastroesophageal varices: a cross-sectional study. BMC Med Imaging 2021;21:120. [PMID: 34372801 DOI: 10.1186/s12880-021-00655-8] [Reference Citation Analysis]
222 Ahmed HS, Wahab EA, Elhady HA, Elgerby MM. Association of genetic polymorphism of BCL-2 (rs2279115) with susceptibility to HCV-related hepatocellular carcinoma. Immunol Res 2020;68:189-97. [PMID: 32623689 DOI: 10.1007/s12026-020-09143-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Xiang F, Sun J, Chen PH, Han P, Zheng H, Cai S, Kirk GD. Early Elevation of Fibrosis-4 Liver Fibrosis Score Is Associated With Adverse Outcomes Among Patients With Coronavirus Disease 2019. Clin Infect Dis 2021;73:e594-601. [PMID: 33909004 DOI: 10.1093/cid/ciaa1710] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
224 Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep 2021;11:15938. [PMID: 34354193 DOI: 10.1038/s41598-021-95581-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
225 Barbosa WF, Andrade VG, Braz AMM, Winckler FC, Barbosa LR, Golim MA, Silveira LVA, Simões RP, Silva GF. Cirrhosis regression after SVR with indirect methods of fibrosis analysis: How far is it real? Clin Exp Med 2021. [PMID: 34347205 DOI: 10.1007/s10238-021-00749-1] [Reference Citation Analysis]
226 Abdelsameea E, Alsebaey A, Abdel-samiee M, Abdel-razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Review of Anti-infective Therapy 2021;19:1053-9. [DOI: 10.1080/14787210.2021.1864326] [Reference Citation Analysis]
227 Hanai T, Hiraoka A, Shiraki M, Sugimoto R, Taniki N, Hiramatsu A, Nakamoto N, Iwasa M, Chayama K, Shimizu M. Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan. J Clin Med 2021;10:3448. [PMID: 34362231 DOI: 10.3390/jcm10153448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
228 Abdelsameea E, Alsebaey A, Abdel-samiee M, Abdel-razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Review of Anti-infective Therapy 2021;19:1053-1059. [DOI: 10.1080/14787210.2021.1864326] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
229 Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 2021. [PMID: 34337887 DOI: 10.1002/jcsm.12754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
230 Hwang J, Yoon HM, Kim KM, Oh SH, Namgoong JM, Kim DY, Cho YA. Assessment of native liver fibrosis using ultrasound elastography and serological fibrosis indices in children with biliary atresia after the Kasai procedure. Acta Radiol 2021;62:1088-96. [PMID: 32811156 DOI: 10.1177/0284185120948489] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
231 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
232 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
233 Tan LJ, Jung H, Kim SA, Shin S. The Association Between Coffee Consumption and Nonalcoholic Fatty Liver Disease in the South Korean General Population. Mol Nutr Food Res 2021;:e2100356. [PMID: 34319647 DOI: 10.1002/mnfr.202100356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Nirei K, Kanda T, Masuzaki R, Mizutani T, Moriyama M. Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. Medicina (Kaunas) 2021;57:761. [PMID: 34440967 DOI: 10.3390/medicina57080761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
235 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
236 Vahedian-Azimi A, Shojaie S, Banach M, Heidari F, Cicero AFG, Khoshfetrat M, Jamialahmadi T, Sahebkar A. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med 2021;53:1227-42. [PMID: 34296976 DOI: 10.1080/07853890.2021.1956686] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
237 Schreiner AD, Livingston S, Zhang J, Gebregziabher M, Marsden J, Koch DG, Petz CA, Durkalski-Mauldin VL, Mauldin PD, Moran WP. Identifying Patients at Risk for Fibrosis in a Primary Care NAFLD Cohort. J Clin Gastroenterol 2023;57:89-96. [PMID: 34294656 DOI: 10.1097/MCG.0000000000001585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 Ong SY, Khoo T, Nicoll AJ, Gurrin L, Worland T, Pateria P, Ramm LE, Testro A, Anderson GJ, Skoien R, Powell LW, Ramm GA, Olynyk JK, Delatycki MB. Utility and limitations of Hepascore and transient elastography to detect advanced hepatic fibrosis in HFE hemochromatosis. Sci Rep 2021;11:14654. [PMID: 34282177 DOI: 10.1038/s41598-021-94083-x] [Reference Citation Analysis]
239 Sterling RK, Shin D, Shin Y, French E, Stevens MP, Bajaj JS, DeWit M, Sanyal AJ. Fibrosis-4 Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. Hepatol Commun 2021;5:1605-15. [PMID: 34510829 DOI: 10.1002/hep4.1737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
240 Zhang C, Yang M. Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci 2021;22:7571. [PMID: 34299189 DOI: 10.3390/ijms22147571] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
241 French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS 2021;35:1433-8. [PMID: 33710024 DOI: 10.1097/QAD.0000000000002869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Piselli P, Serraino D, Fusco M, Girardi E, Pirozzi A, Toffolutti F, Cimaglia C, Taborelli M; Collaborating Study Group. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infect Dis 2021;21:667. [PMID: 34238231 DOI: 10.1186/s12879-021-06336-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
243 Kakisaka K, Suzuki Y, Abe H, Eto H, Kanazawa J, Takikawa Y. Serum alpha-fetoprotein increases prior to fibrosis resolution in a patient with acute liver failure. Clin J Gastroenterol 2021;14:1470-5. [PMID: 34212265 DOI: 10.1007/s12328-021-01467-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101578. [PMID: 33272891 DOI: 10.1016/j.clinre.2020.11.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
245 AbdAllah M, Alboraie M, Abdel-Razek W, Hassany M, Ammar I, Kamal E, Alalfy M, Okasha A, El Akel W, Shaaban E, Elbaz T, Hefny Z, Gomaa A, El-Bendary M, El-Serafy M, Esmat G, Doss W, El-Sayed MH. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver Int 2021;41:1494-7. [PMID: 33905164 DOI: 10.1111/liv.14913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
246 Vannier AGL, PeBenito A, Fomin V, Chung RT, Schaefer E, Goodman RP, Luther J. An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL. Clin Exp Med 2021. [PMID: 34212294 DOI: 10.1007/s10238-021-00736-6] [Reference Citation Analysis]
247 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
248 Anugwom C, Campbell C, Debes JD. Assessment of subclinical effects of Hepatitis E virus infection in the United States. J Viral Hepat 2021;28:1091-7. [PMID: 33894038 DOI: 10.1111/jvh.13519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Chin J, Powell LW, Ramm LE, Hartel GF, Olynyk JK, Ramm GA. Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE. Clin Gastroenterol Hepatol 2021;19:1459-1468.e5. [PMID: 32745684 DOI: 10.1016/j.cgh.2020.07.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
250 Roh YH, Kang BK, Jun DW, Lee CM, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep 2021;11:13616. [PMID: 34193951 DOI: 10.1038/s41598-021-93038-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
251 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 80] [Article Influence: 35.0] [Reference Citation Analysis]
252 Guo G, Lei Z, Tang X, Ma W, Si A, Yang P, Li Q, Geng Z, Zhou J, Cheng Z. External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. J Cancer 2021;12:5260-7. [PMID: 34335942 DOI: 10.7150/jca.58726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Ghoneem E, Saleh A, El-etreby SA, Mortada MI, Ghannam MA, El-ashwah S, Eisa N. Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00124-5] [Reference Citation Analysis]
254 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
255 Qiao L, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shang J, Liu J, Yan H, Gu W, Zhang Y, Xiang X, Hou Y, Zhang Q, Xiong Y, Zou C, Chen J, Huang Z, Jiang X, Luo S, Chen Y, Gao N, Liu C, Yuan W, Mei X, Li J, Li T, Zheng R, Zhou X, Chen J, Deng G, Zhang W, Li H. Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. Front Med (Lausanne) 2021;8:704452. [PMID: 34249983 DOI: 10.3389/fmed.2021.704452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Kikukawa K, Uchida-Kobayashi S, Tamori A, Yoshida K, Kotani K, Motoyama H, Kozuka R, Hagihara A, Fujii H, Morikawa H, Enomoto M, Murakami Y, Kawada N. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. Ann Hepatol 2020;19:367-72. [PMID: 32444247 DOI: 10.1016/j.aohep.2020.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
257 Fuster D, García-Calvo X, Zuluaga P, Bolao F, Muga R. Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World J Gastroenterol 2021; 27(23): 3223-3237 [PMID: 34163107 DOI: 10.3748/wjg.v27.i23.3223] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Gouvêa AFTB, Filho RC, Machado DM, Bononi do Carmo F, Beltrão SV, Sampaio L, de Moraes-Pinto MI, Succi RCM. Assessment of liver disease by non-invasive methods in perinatally infected Brazilian adolescents and young adults living with Human Immunodeficiency Virus (HIV). Braz J Infect Dis 2021;25:101589. [PMID: 34147474 DOI: 10.1016/j.bjid.2021.101589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
260 Xu K, Shi M, Zhang W, Shi Y, Dong Q, Shen X, Chen X, Lin J. Preoperative Fibrosis-4 (FIB-4) Evaluation May Be Helpful to Evaluate Prognosis of Gastric Cancer Patients Undergoing Operation: A Retrospective Study. Front Oncol 2021;11:655343. [PMID: 34221972 DOI: 10.3389/fonc.2021.655343] [Reference Citation Analysis]
261 Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Endocrinol Metab (Seoul) 2020;35:165-76. [PMID: 32207277 DOI: 10.3803/EnM.2020.35.1.165] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
262 Romero-Cristóbal M, Clemente-Sánchez A, Piñeiro P, Cedeño J, Rayón L, Del Río J, Ramos C, Hernández DA, Cova M, Caballero A, Garutti I, García-Olivares P, Hortal J, Guerrero JE, García R, Bañares R, Rincón D. Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. Therap Adv Gastroenterol 2021;14:17562848211023410. [PMID: 34178116 DOI: 10.1177/17562848211023410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
263 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y. AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. BMC Cancer 2021;21:699. [PMID: 34126947 DOI: 10.1186/s12885-021-08401-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
264 Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN, Hung CH, Chang TS. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol 2021;21:259. [PMID: 34118889 DOI: 10.1186/s12876-021-01837-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
265 Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines 2021;9:660. [PMID: 34201309 DOI: 10.3390/biomedicines9060660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
266 Lee SH, Shin HP, Lee JI. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. Antivir Chem Chemother 2020;28:2040206620974835. [PMID: 33215505 DOI: 10.1177/2040206620974835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Li X, Xing Y, Zhou D, Xiao H, Zhou Z, Han Z, Sun X, Li S, Zhang L, Li Z, Zhang P, Zhang J, Zhang N, Cao X, Zao X, Du H, Tong G, Chi X, Gao Y, Ye Y. A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. Front Med (Lausanne) 2021;8:688091. [PMID: 34150818 DOI: 10.3389/fmed.2021.688091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Dong B, Huang S, Chang J, Chen X, Yan J. Comparison of Sound Touch Elastography, Sound Touch Quantify, and 4 Serum Fibrosis Indexes for the Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B. Ultrasound Q 2021;37:123-8. [PMID: 34057912 DOI: 10.1097/RUQ.0000000000000485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Evrimler S, Swensson JK, Are VS, Tirkes T, Vuppalanchi R, Akisik F. Quantitative assessment of disease severity of primary sclerosing cholangitis with T1 mapping and extracellular volume imaging. Abdom Radiol (NY) 2021;46:2433-43. [PMID: 33135100 DOI: 10.1007/s00261-020-02839-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
270 Davison BA, Edwards C, Loomba R, Harrison SA, Cotter G, Alkhouri N, Koch GG, Dittrich HC. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. JGH Open 2021;5:740-9. [PMID: 34263067 DOI: 10.1002/jgh3.12575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
271 Dong BT, Huang S, Lyu GR, Qin R, Gu JH. Assessment of liver fibrosis with liver and spleen stiffness measured by sound touch elastography, serum fibrosis markers in patients with chronic hepatitis B. J Dig Dis 2021;22:342-50. [PMID: 33851510 DOI: 10.1111/1751-2980.12991] [Reference Citation Analysis]
272 Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology 2021;73:2238-50. [PMID: 32978796 DOI: 10.1002/hep.31576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
273 Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. Nephrol Dial Transplant 2021;36:1097-103. [PMID: 33009910 DOI: 10.1093/ndt/gfaa165] [Reference Citation Analysis]
274 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Guerra-ruiz AR, Casals G, Iruzubieta P, Lalana M, Leis A, López RM, Crespo J, Morales-ruiz M. Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:209-219. [DOI: 10.1515/almed-2020-0062] [Reference Citation Analysis]
276 Guerra-ruiz AR, Casals G, Iruzubieta P, Lalana M, Leis A, López RM, Crespo J, Morales-ruiz M. Biochemical assessment of metabolic associated fatty liver disease. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:199-208. [DOI: 10.1515/almed-2021-0009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 Wu J, Chen Y, Zuo C, Kuang N, Li R, Li Q, Ruan J, Cui E, Xu R, Yu J. A novel index for staging hepatitis B related liver cirrhosis in patients with hepatocellular carcinoma. Sci Prog 2021;104:368504211018052. [PMID: 34003700 DOI: 10.1177/00368504211018052] [Reference Citation Analysis]
278 Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, Liu H, Shang Q, Yu Z, Jiang L, Xiao G, Li L, Chen L, Wang X, Li Z, Chen D, Dong Z, An L, Tan L, Chen Y, Yang Y. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine 2021;67:103389. [PMID: 34004423 DOI: 10.1016/j.ebiom.2021.103389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
279 Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
280 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
281 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
282 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
283 Marella HK, Reddy YK, Jiang Y, Ganguli S, Podila PSB, Snell PD, Kovalic AJ, Cholankeril G, Singal AK, Nair S, Maliakkal B, Satapathy SK. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00165. [PMID: 32352687 DOI: 10.14309/ctg.0000000000000165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Bagheri Lankarani K, Honarvar B, Rouhezamin MR, Raeisi Shahraki H, Seifi V, Geramizadeh B, Salahi H, Nikeghbalian S, Shamsaeefar A, Keshani P, Malekhosseini SA. Mortality and Its Determinants in Adult Patients with End-stage Liver Disease on Waiting List for Liver Transplantation: A Preliminary Report on Baseline Data. Shiraz E-Med J 2021;22. [DOI: 10.5812/semj.110254] [Reference Citation Analysis]
285 Ma Q, Liao X, Shao C, Lin Y, Wu T, Sun Y, Feng ST, Ye J, Zhong B. Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:215. [PMID: 33971815 DOI: 10.1186/s12876-021-01790-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
286 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
287 Hahn JA, Murnane PM, Vittinghoff E, Muyindike WR, Emenyonu NI, Fatch R, Chamie G, Haberer JE, Francis JM, Kapiga S, Jacobson K, Myers B, Couture MC, DiClemente RJ, Brown JL, So-Armah K, Sulkowski M, Marcus GM, Woolf-King S, Cook RL, Richards VL, Molina P, Ferguson T, Welsh D, Piano MR, Phillips SA, Stewart S, Afshar M, Page K, McGinnis K, Fiellin DA, Justice AC, Bryant K, Saitz R. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. Alcohol Clin Exp Res 2021;45:1166-87. [PMID: 33837975 DOI: 10.1111/acer.14611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
288 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
289 Torti C, Scaglione V, Cesana BM, Costa C, Marascio N, Schiaroli E, Busti C, Bastianelli S, Mazzitelli M, Trecarichi EM, Francisci D. Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. Health Sci Rep 2021;4:e273. [PMID: 33969232 DOI: 10.1002/hsr2.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
290 Hsieh YC, Lee KC, Su CW, Lan KH, Huo TI, Wang YJ, Huang HC, Lin HC, Chu CJ, Huang YH, Hou MC. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J Chin Med Assoc 2021;84:472-7. [PMID: 33742989 DOI: 10.1097/JCMA.0000000000000517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
291 Cho Y, Kabata D, Ehara E, Yamamoto A, Mizuochi T, Mushiake S, Kusano H, Kuwae Y, Suzuki T, Uchida-Kobayashi S, Morikawa H, Amano-Teranishi Y, Kioka K, Jogo A, Isoura Y, Hamazaki T, Murakami Y, Tokuhara D. Assessing liver stiffness with conventional cut-off values overestimates liver fibrosis staging in patients who received the Fontan procedure. Hepatol Res 2021;51:593-602. [PMID: 33677839 DOI: 10.1111/hepr.13627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Abdel Moez AT, El Hawary YA, Al Balakosy AM. Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients? Eur J Gastroenterol Hepatol 2021;33:727-30. [PMID: 32558698 DOI: 10.1097/MEG.0000000000001790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
293 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Short-term Effects of Hepatic Arterial Buffer Responses Induced by Partial Splenic Embolization on the Hepatic Function of Patients with Cirrhosis According to the Child-Pugh Classification. Intern Med 2021;60:1331-42. [PMID: 33281164 DOI: 10.2169/internalmedicine.6267-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
294 Wang J, Wu M, Linghu R, Chang J, Wu M, Feng C, Ren X, Liu C, Lin J, Song T, Gu J, Zhang Y, Fang Y, Ma S, Hu P, Wu L, Han X, Chen K, Shi Q, Zhang R, Zhou Q, Du R, Gao Y, Jing X, Yang S, Zhou C, Zheng J, Liang P, Zheng RQ. Usefulness of New Shear Wave Elastography Technique for Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B: A Prospective Multicenter Study. Ultraschall Med 2021. [PMID: 33910257 DOI: 10.1055/a-1376-6734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, Butsashvili M, Metreveli D, Gvinjilia L, Shadaker S, Nasrullah M, Adamia E, Zeuzem S, Afdhal N, Arora S, Thornton K, Skaggs B, Kuchuloria T, Lagvilava M, Sergeenko D, Averhoff F. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. Clin Infect Dis 2020;71:1263-8. [PMID: 31563938 DOI: 10.1093/cid/ciz956] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
296 Zenovia S, Stanciu C, Sfarti C, Singeap AM, Cojocariu C, Girleanu I, Dimache M, Chiriac S, Muzica CM, Nastasa R, Huiban L, Cuciureanu T, Trifan A. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2021;11:787. [PMID: 33925569 DOI: 10.3390/diagnostics11050787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
297 Husa P, Snopkova S, Zavrelova J, Zlamal F, Svacinka R, Husa P. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021;165:146-51. [PMID: 33928944 DOI: 10.5507/bp.2021.023] [Reference Citation Analysis]
298 Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, Tanaka J. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. Clin Transl Gastroenterol 2021;12:e00337. [PMID: 33888672 DOI: 10.14309/ctg.0000000000000337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
299 Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL. Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. Infect Dis Ther 2021;10:1001-13. [PMID: 33881712 DOI: 10.1007/s40121-021-00441-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterol 2021;21:177. [PMID: 33865328 DOI: 10.1186/s12876-021-01761-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
301 Parikh NS, Koh I, VanWagner LB, Elkind MSV, Zakai NA, Cushman M. Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. J Stroke Cerebrovasc Dis 2021;30:105788. [PMID: 33866274 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105788] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
302 Zhong W, Zhang F, Huang K, Zou Y, Liu Y. Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and FIB-4) Model to Predict Posthepatectomy Liver Failure Grade B-C in Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:6665267. [PMID: 34221013 DOI: 10.1155/2021/6665267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
303 Yang L, Ling W, He D, Lu C, Ma L, Tang L, Luo Y, Chen S. Shear wave-based sound touch elastography in liver fibrosis assessment for patients with autoimmune liver diseases. Quant Imaging Med Surg 2021;11:1532-42. [PMID: 33816189 DOI: 10.21037/qims-20-521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
304 Lesko CR, Nance RM, Lau B, Fojo AT, Hutton HE, Delaney JAC, Crane HM, Cropsey KL, Mayer KH, Napravnik S, Geng E, Mathews WC, McCaul ME, Chander G; CNICS. Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States. AIDS Behav 2021;25:1072-82. [PMID: 33064249 DOI: 10.1007/s10461-020-03065-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
305 Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int 2021;41:731-42. [PMID: 33497019 DOI: 10.1111/liv.14799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
306 Ohashi K, Ishikawa T, Hoshii A, Hokari T, Noguchi H, Suzuki M, Hirosawa H, Imai M, Mitobe Y, Yoshida T. Optimal Skeletal Muscle Mass Index Cut-Off Values for Presarcopenia Evaluated by Computed Tomography against Dual-Energy X-ray Absorptiometry in Patients with Chronic Liver Disease. J Clin Med 2021;10:1419. [PMID: 33915929 DOI: 10.3390/jcm10071419] [Reference Citation Analysis]
307 Lee HJ, Lee DC, Kim CO. Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. Front Endocrinol (Lausanne) 2021;12:599339. [PMID: 33868162 DOI: 10.3389/fendo.2021.599339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
308 Li X, Guo Y, Wang X, Ge A, Wang H, Fan K, Guo C. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infect Dis (Lond) 2021;53:546-54. [PMID: 33783293 DOI: 10.1080/23744235.2021.1901981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
309 Catanzaro R, Aleo A, Sciuto M, Zanoli L, Balakrishnan B, Marotta F. FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. Clin Exp Hepatol 2021;7:111-6. [PMID: 34027123 DOI: 10.5114/ceh.2021.104543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
310 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
311 Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 2021;12:20420188211000243. [PMID: 33815743 DOI: 10.1177/20420188211000243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
312 Sung MJ, Park JY, Lee HW, Kim BK, Kim DY, Ahn SH, Kim SU. Predictors of Sarcopenia in an Obese Asian Population. Nutr Cancer 2021;:1-10. [PMID: 33733940 DOI: 10.1080/01635581.2021.1895232] [Reference Citation Analysis]
313 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
314 Umbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. J Infect Dis 2020;222:S52-62. [PMID: 32645163 DOI: 10.1093/infdis/jiaa249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
315 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
316 Fujita K, Yamasaki K, Morishita A, Shi T, Tani J, Nishiyama N, Kobara H, Himoto T, Yatsuhashi H, Masaki T. Albumin platelet product as a novel score for liver fibrosis stage and prognosis. Sci Rep 2021;11:5345. [PMID: 33674669 DOI: 10.1038/s41598-021-84719-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
317 Dasgupta S, Imamura M, Gorstein E, Nakahara T, Tsuge M, Churkin A, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Dahari H, Chayama K. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. J Infect Dis 2020;222:1165-9. [PMID: 32363394 DOI: 10.1093/infdis/jiaa219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
318 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Satapathy SK, Marella HK, Heda RP, Ganguli S, Kirthi Reddy Y, Podila PSB, Clark I, Maliakkal B. African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians. Eur J Gastroenterol Hepatol 2021;33:388-98. [PMID: 32317586 DOI: 10.1097/MEG.0000000000001735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
320 Takahashi H, Kanda T, Matsumoto N, Mizutani T, Kaneko T, Honda M, Yamana Y, Ishii T, Kumagawa M, Sasaki R, Masuzaki R, Nirei K, Yamagami H, Ogawa M, Matsuoka S, Moriyama M. HCV GT1b-patient with alanine aminotransferase elevation and sustained virologic response achieved by grazoprevir/elbasvir discontinuation. Future Virology 2021;16:161-165. [DOI: 10.2217/fvl-2020-0181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
321 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
322 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
323 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel) 2021;11:143. [PMID: 33672864 DOI: 10.3390/life11020143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
324 Kishino K, Enomoto H, Shimono Y, Moriwaki EI, Nishikawa H, Nishimura T, Iwata Y, Iijima H, Nishiguchi S. Association of an Overhydrated State With the Liver Fibrosis and Prognosis of Cirrhotic Patients. In Vivo 2020;34:1347-53. [PMID: 32354929 DOI: 10.21873/invivo.11912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
325 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease. Biomed Rep 2021;14:34. [PMID: 33732453 DOI: 10.3892/br.2021.1410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Oh S, Tsujimoto T, Kim B, Uchida F, Suzuki H, Iizumi S, Isobe T, Sakae T, Tanaka K, Shoda J. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Rep 2021;3:100253. [PMID: 33898958 DOI: 10.1016/j.jhepr.2021.100253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
327 Xiang X, Yang X, Shen M, Huang C, Liu Y, Fan X, Yang L. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2021;2021:6691425. [PMID: 33542908 DOI: 10.1155/2021/6691425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
328 Fujimoto K, Shiinoki T, Yuasa Y, Tanaka H. Estimation of liver elasticity using the finite element method and four-dimensional computed tomography images as a biomarker of liver fibrosis. Med Phys 2021;48:1286-98. [PMID: 33449406 DOI: 10.1002/mp.14723] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Dong B, Lyu G, Chen Y, Lin G, Wang H, Qin R, Gu J. Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B: a meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1077-89. [PMID: 33487039 DOI: 10.1080/17474124.2021.1880894] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
330 Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med 2021;22:445-56. [PMID: 33529485 DOI: 10.1111/hiv.13060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
331 Syed-Abdul MM, Jacome-Sosa M, Hu Q, Gaballah AH, Winn NC, Lee NT, Mucinski JM, Manrique-Acevedo C, Lastra G, Anderson JM, Al Juboori A, Bartholow BD, Parks EJ. The Tailgate Study: Differing metabolic effects of a bout of excessive eating and drinking. Alcohol 2021;90:45-55. [PMID: 33232792 DOI: 10.1016/j.alcohol.2020.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. [PMID: 33595662 DOI: 10.1001/jamanetworkopen.2020.37512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
333 Darweesh SK, Elsabaawy MA, Eltahawy MA, Ghanem HS, Abdel-Razek W. Serum ammonia as a non-invasive marker for early prediction of esophageal varices. Eur J Gastroenterol Hepatol 2021;32:230-6. [PMID: 32243345 DOI: 10.1097/MEG.0000000000001715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
334 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Hasegawa T, Toyota J. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol 2021;36:367-75. [PMID: 32991760 DOI: 10.1111/jgh.15280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
335 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML, Younes Z, Abdelmalek M. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. Am J Gastroenterol 2021;116:254-62. [PMID: 33284184 DOI: 10.14309/ajg.0000000000001054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
336 Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology 2021;73:548-59. [PMID: 33125745 DOI: 10.1002/hep.31608] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
337 Gomes C, Ginzberg D, Wong RJ. Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience. J Transl Int Med 2020;8:261-7. [PMID: 33511053 DOI: 10.2478/jtim-2020-0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
339 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
340 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
341 Ding R, Zheng J, Huang D, Wang Y, Li X, Zhou X, Yan L, Lu W, Yang Z, Zhang Z. INR-to-platelet ratio (INPR) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis B. Int J Med Sci 2021;18:1159-66. [PMID: 33526976 DOI: 10.7150/ijms.51799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
342 Huang C, Liu L, Wang H, Fang M, Feng H, Li Y, Wang M, Tong L, Xiao X, Wang Z, Xu X, He Y, Gao C. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study. Clin Chem Lab Med 2021;59:1087-97. [PMID: 33554541 DOI: 10.1515/cclm-2020-1588] [Reference Citation Analysis]
343 Chen HW, Chiu YL, Hsieh TY, Chen PJ, Huang TY, Lin HH, Shih YL, Lin JC. Relationships Between Vitamin D Status and Cytokine: Results from Interferon-Based Therapy in Non-Cirrhotic, Treatment-Naïve Patients with Chronic Hepatitis C Infection. J Inflamm Res 2020;13:1207-18. [PMID: 33402842 DOI: 10.2147/JIR.S283768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
344 Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Clin Infect Dis 2020;70:1208-14. [PMID: 31056696 DOI: 10.1093/cid/ciz359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
345 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
346 Tsai IT, Hung WC, Lu YC, Wu CC, Lee TL, Hsuan CF, Yu TH, Wei CT, Chung FM, Lee YJ, Wang CP. Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function. Int J Med Sci 2021;18:1-7. [PMID: 33390768 DOI: 10.7150/ijms.50646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
347 Goldschmidt I, Baumann U. Role of Biomarkers in Monitoring Liver Allograft Function. Pediatric Liver Transplantation 2021. [DOI: 10.1016/b978-0-323-63671-1.00030-6] [Reference Citation Analysis]
348 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Martínez-mier G, Esquivel-torres S, Casanova-sánchez I, Escobar-ríos A, Troche-gutiérrez J, Yoldi-aguirre C. Carcinoma hepatocelular en hígado no cirrótico: características clínicas y resultados en Veracruz, México. Revista de Gastroenterología de México 2021;86:4-12. [DOI: 10.1016/j.rgmx.2019.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Castera L. Assessment of Liver Disease Severity. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_1] [Reference Citation Analysis]
351 Verma K, Rungta S, Kumari S, Deep A, Swaroop S. APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. J Family Med Prim Care 2021;10:4082. [DOI: 10.4103/jfmpc.jfmpc_666_21] [Reference Citation Analysis]
352 Park EJ, Kim SH, Park SJ, Baek TW. Texture Analysis of Gray-Scale Ultrasound Images for Staging of Hepatic Fibrosis. J Korean Soc Radiol 2021;82:116. [DOI: 10.3348/jksr.2019.0185] [Reference Citation Analysis]
353 Kumada T, Toyoda H, Yasuda S, Miyake N, Tada T, Ito T, Tanaka J. Serial changes in FIB‐4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy. GastroHep 2021;3:37-49. [DOI: 10.1002/ygh2.434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Martínez-mier G, Esquivel-torres S, Casanova-sánchez I, Escobar-ríos A, Troche-gutiérrez J, Yoldi-aguirre C. Hepatocellular carcinoma in the noncirrhotic liver: Clinical features and outcomes in Veracruz, Mexico. Revista de Gastroenterología de México (English Edition) 2021;86:4-12. [DOI: 10.1016/j.rgmxen.2019.11.006] [Reference Citation Analysis]
355 Abdelsameea E, Alsebaey A, Abdel-Samiee M, Abdel-Razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Rev Anti Infect Ther 2021;19:1053-9. [PMID: 33307880 DOI: 10.1080/14787210.2021.1864326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
356 Fahmy DM, Shokeir M, El Zeiny SM, Jonas MM, Abdallah A. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection. J Pediatr 2021;231:110-6. [PMID: 33347957 DOI: 10.1016/j.jpeds.2020.12.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Liu TW, Huang CF, Yeh ML, Tsai PC, Jang TY, Huang JF, Dai CY, Chuang WL, Yu ML. Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. BMJ Open Gastroenterol 2020;7:e000543. [PMID: 33323472 DOI: 10.1136/bmjgast-2020-000543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
358 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
359 Abbas SH, Pickett E, Lomas DA, Thorburn D, Gooptu B, Hurst JR, Marshall A. Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. BMJ Open Respir Res 2020;7:e000820. [PMID: 33323365 DOI: 10.1136/bmjresp-2020-000820] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
360 Sasaki R, Miyaaki H, Narita S, Fukushima M, Haraguchi M, Miuma S, Hidaka M, Eguchi S, Okudaira S, Abe K, Nakao K. Serum Mac-2 binding protein glycosylation isomer as a biomarker of fibrosis in living donor liver transplant graft. Clin Transplant 2021;35:e14175. [PMID: 33247961 DOI: 10.1111/ctr.14175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Wang S, Huang Y, Hu W, Mao H, McAlindon ME, Liu Y, Yang L, Zhang C, Xu M, He C, Dang T, Wu B, Ji D, Zhang L, Mao X, Zhang L, Liu C, Xu D, Li Y, Li G, Han J, Lv F, Liang X, Jin S, Zhang S, Tai FWD, Xu Q, Yang C, Wang G, Wang L, Li B, Yang H, Xie P, Deng L, Ren L, Chang Z, Wang X, Wang S, Gao X, Li J, Zhu L, Wang F, Zhang L, Zhang G, Jiang X, Pan J, Meng W, Li X, Hou J, Dray X, Liao Z, Qi X. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): A prospective multicenter study. Lancet Reg Health West Pac 2021;6:100072. [PMID: 34327406 DOI: 10.1016/j.lanwpc.2020.100072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
362 Levy JJ, Azizgolshani N, Andersen MJ Jr, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak CA, Christensen BC, Vaickus LJ. A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. Mod Pathol 2021;34:808-22. [PMID: 33299110 DOI: 10.1038/s41379-020-00718-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
363 Abe K, Wakabayashi H, Nakayama H, Suzuki T, Kuroda M, Yoshida N, Tojo J, Kogure A, Rai T, Saito H, Mukai S, Fujita M, Hayashi M, Takahashi A, Ohira H. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One 2020;15:e0243473. [PMID: 33284844 DOI: 10.1371/journal.pone.0243473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
364 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
365 Liu Y, Ning Z, Örmeci N, An W, Yu Q, Han K, Huang Y, Liu D, Liu F, Li Z, Ding H, Luo H, Zuo C, Liu C, Wang J, Zhang C, Ji J, Wang W, Wang Z, Wang W, Yuan M, Li L, Zhao Z, Wang G, Li M, Liu Q, Lei J, Liu C, Tang T, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Liu Z, Teng G, Chen Y, Hou J, Li X, He X, Dong J, Tian J, Liang P, Ju S, Zhang Y, Qi X. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2998-3007.e5. [PMID: 32205218 DOI: 10.1016/j.cgh.2020.03.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
366 Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
367 Zain SM, Tan H, Mohamed Z, Chan W, Mahadeva S, Basu RC, Mohamed R. Use of simple scoring systems for a public health approach in the management of non‐alcoholic fatty liver disease patients. JGH Open 2020;4:1155-1161. [DOI: 10.1002/jgh3.12414] [Reference Citation Analysis]
368 Abdelsameea E, Alsebaey A, Abdel-Razek W, Ehsan N, Morad W, Salama M, Waked I. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. Eur J Gastroenterol Hepatol 2020;32:1553-8. [PMID: 31972660 DOI: 10.1097/MEG.0000000000001672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
369 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020; 26(44): 7046-7060 [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
370 Leuştean A, Popescu C, Nichita L, Tilişcan C, Aramă V. Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy. Exp Ther Med 2021;21:99. [PMID: 33363610 DOI: 10.3892/etm.2020.9531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
371 Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson AJ. Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS One 2020;15:e0242101. [PMID: 33206696 DOI: 10.1371/journal.pone.0242101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
372 Martinez-Urbistondo D, Suarez Del Villar R, Argemí J, Daimiel L, Ramos-López O, San-Cristobal R, Villares P, Martinez JA. Antioxidant Lifestyle, Co-Morbidities and Quality of Life Empowerment Concerning Liver Fibrosis. Antioxidants (Basel) 2020;9:E1125. [PMID: 33202851 DOI: 10.3390/antiox9111125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
373 Wang SF, Huang YT, Huang CH, Chang SH, Lin CY. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med 2020;8:1223. [PMID: 33178755 DOI: 10.21037/atm-20-2444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
374 Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Kaohsiung J Med Sci. 2021;37:334-345. [PMID: 33151016 DOI: 10.1002/kjm2.12315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
375 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
376 Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infect Dis Ther 2021;10:269-80. [PMID: 33141401 DOI: 10.1007/s40121-020-00364-9] [Reference Citation Analysis]
377 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
378 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
379 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus. Intern Med 2020;59:2653-60. [PMID: 33132304 DOI: 10.2169/internalmedicine.5102-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
380 Hara T, Ohara T, Taniguchi M, Sakai T, Oka K, Iwai N, Tsuji T, Okuda T, Komaki T, Sakagami J, Kagawa K. Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapy. Case Reports Hepatol 2020;2020:8824974. [PMID: 33123390 DOI: 10.1155/2020/8824974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
381 Ishida K, Namisaki T, Murata K, Fujimoto Y, Takeda S, Enomoto M, Ogawa H, Takagi H, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Sawada Y, Kitagawa K, Sato S, Nishimura N, Takaya H, Kaji K, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. J Clin Med 2020;9:E3510. [PMID: 33138335 DOI: 10.3390/jcm9113510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
382 Ferguson TF, Rosen E, Carr R, Brashear M, Simon L, Theall KP, Ronis MJ, Welsh DA, Molina PE. Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study. Alcohol Alcohol 2020;55:28-36. [PMID: 31812989 DOI: 10.1093/alcalc/agz089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
383 Ishikawa T, Endo S, Imai M, Azumi M, Nozawa Y, Sano T, Iwanaga A, Honma T, Yoshida T. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. Intern Med 2020;59:2465-9. [PMID: 33055469 DOI: 10.2169/internalmedicine.5094-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
384 Kim HY, Baik SJ, Lee HA, Lee BK, Lee HS, Kim TH, Yoo K. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease. Sci Rep 2020;10:17491. [PMID: 33060775 DOI: 10.1038/s41598-020-74659-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
385 Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
386 Belmonte I, Nuñez A, Barrecheguren M, Esquinas C, Pons M, López-Martínez RM, Ruiz G, Blanco-Grau A, Ferrer R, Genescà J, Miravitlles M, Rodríguez-Frías F. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. Int J Chron Obstruct Pulmon Dis 2020;15:2421-31. [PMID: 33116457 DOI: 10.2147/COPD.S269641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
387 Lim TS, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee JW, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. J Viral Hepat 2020;27:1052-60. [PMID: 32383246 DOI: 10.1111/jvh.13316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
388 Nakagawa M, Nawa N, Takeichi E, Shimizu T, Tsuchiya J, Sato A, Miyoshi M, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Fujiwara T, Watanabe M, Tanaka Y, Asahina Y; Ochanomizu Liver Conference Study Group. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol 2020;55:990-9. [PMID: 32770465 DOI: 10.1007/s00535-020-01715-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
389 Mai R, Lu H, Bai T, Liang R, Lin Y, Ma L, Xiang B, Wu G, Li L, Ye J. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery 2020;168:643-52. [DOI: 10.1016/j.surg.2020.06.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
390 Shibata N, Kondo T, Kazama S, Kimura Y, Oishi H, Arao Y, Kato H, Yamaguchi S, Kuwayama T, Hiraiwa H, Morimoto R, Okumura T, Sumi T, Sawamura A, Shimizu K, Murohara T. Impact of predictive value of Fibrosis-4 index in patients hospitalized for acute heart failure. Int J Cardiol 2021;324:90-5. [PMID: 33007325 DOI: 10.1016/j.ijcard.2020.09.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
391 Ueda N, Kawaoka T, Imamura M, Aikata H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Hayes CN, Yokozaki M, Chayama K. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. BMC Gastroenterol 2020;20:314. [PMID: 32977741 DOI: 10.1186/s12876-020-01459-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
392 Mansour AMF, Bayoumy EM, Elghandour AM, El-talkawy MD, Badr SM, Ahmed AE. Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00044-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
393 Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, Lee BW. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038. [PMID: 32871978 DOI: 10.1097/MD.0000000000021038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
394 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
395 Mada PK, Malus ME, Saldaña Koppel DA, Adley S, Moore M, Alam MJ, Feldman M. Predicting Liver Fibrosis in the Hepatitis C Population: Concordance Analysis Between Noninvasive Scoring Systems and Percutaneous Liver Biopsy. Cureus 2020;12:e10376. [PMID: 33062499 DOI: 10.7759/cureus.10376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
396 Xiang F, Sun J, Chen P, Han P, Zheng H, Cai S, Kirk GD. Early elevation of FIB-4 liver fibrosis score is associated with adverse outcomes among patients with COVID-19.. [DOI: 10.1101/2020.09.01.20186080] [Reference Citation Analysis]
397 Schmoyer CJ, Kumar D, Gupta G, Sterling RK. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. Clin Gastroenterol Hepatol 2020;18:2332-2339.e1. [PMID: 32084602 DOI: 10.1016/j.cgh.2020.02.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
398 Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol 2020;35:1602-9. [PMID: 31975438 DOI: 10.1111/jgh.14991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
399 Shida T, Oshida N, Suzuki H, Okada K, Watahiki T, Oh S, Kim T, Isobe T, Okamoto Y, Ariizumi SI, Yamamoto M, Shoda J. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol Res 2020;50:1032-46. [PMID: 32602214 DOI: 10.1111/hepr.13543] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
400 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
401 Dey R, Sebastiani G, Saha-Chaudhuri P. Inference about time-dependent prognostic accuracy measures in the presence of competing risks. BMC Med Res Methodol 2020;20:219. [PMID: 32859153 DOI: 10.1186/s12874-020-01100-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
402 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
403 Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med 2020;63:188-97. [PMID: 32884438 DOI: 10.33160/yam.2020.08.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
404 Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:970-85. [PMID: 32763196 DOI: 10.1016/S2468-1253(20)30252-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 22.7] [Reference Citation Analysis]
405 Toyoda H, Yasuda S, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yamamoto S, Shiota S, Furoi M, Koyabu T, Furukawa D, Kumada T, Sumida Y. Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: a study in patients with chronic hepatitis C after sustained virologic response. GastroHep 2020. [PMID: 32837333 DOI: 10.1002/ygh2.418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
406 Feng JW, Qu Z, Wu BQ, Sun DL, Jiang Y. The preoperative fibrosis score 4 predicts posthepatectomy liver failure in patients with hepatocellular carcinoma. Ann Hepatol 2019;18:701-7. [PMID: 31167732 DOI: 10.1016/j.aohep.2019.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
407 Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y, Said M. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:1017-22. [PMID: 31789947 DOI: 10.1097/MEG.0000000000001612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
408 Lu HS, Hsin IF, Chen PH, Yang TC, Chang CY, Huang YH, Hou MC. The indocyanine green retention test as a noninvasive marker for esophageal varices in patients with hepatocellular carcinoma. J Chin Med Assoc 2020;83:737-42. [PMID: 32649412 DOI: 10.1097/JCMA.0000000000000378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
409 Chen YP, Huang LW, Lin XY, Hu XM, Liang XE, Jiang RL. Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis. J Viral Hepat 2020;27:826-36. [PMID: 32187804 DOI: 10.1111/jvh.13293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
410 Yang L, Li J, Ma L, Xiang H, He D, Lu C, Tang L, Luo Y, Chen S. Noninvasive assessment of liver fibrosis in chronic hepatitis B carriers with sound touch elastography: study of surgical pathology specimens. Expert Rev Med Devices 2020;17:845-53. [PMID: 32686517 DOI: 10.1080/17434440.2020.1798226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
411 Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020;52:513-26. [PMID: 32598051 DOI: 10.1111/apt.15830] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
412 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
413 Himoto T, Miyatake K, Maeba T, Masaki T. Verification of the Nutritional and Dietary Factors Associated with Skeletal Muscle Index in Japanese Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:3576974. [PMID: 32695733 DOI: 10.1155/2020/3576974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
414 Kang NL, Zhang JM, Lin MX, Chen XD, Huang ZX, Zhu YY, Liu YR, Zeng DW. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol 2020; 26(27): 3952-3962 [PMID: 32774069 DOI: 10.3748/wjg.v26.i27.3952] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
415 Parikh NS, Kumar S, Rosenblatt R, Zhao C, Cohen DE, Iadecola C, Kamel H. Association between liver fibrosis and cognition in a nationally representative sample of older adults. Eur J Neurol 2020;27:1895-903. [DOI: 10.1111/ene.14384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
416 Mai RY, Zeng J, Mo YS, Liang R, Lin Y, Wu SS, Piao XM, Gao X, Wu GB, Li LQ, Ye JZ. Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Ther Clin Risk Manag 2020;16:639-49. [PMID: 32764948 DOI: 10.2147/TCRM.S257218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
417 Androutsakos T, Schina M, Pouliakis A, Kontos A, Sipsas N, Hatzis G. Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. Curr HIV Res 2019;17:173-82. [PMID: 31549590 DOI: 10.2174/1570162X17666190809153245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
418 Casellas-Robert M, Lim C, Lopez-Ben S, Lladó L, Salloum C, Codina-Font J, Comas-Cufí M, Ramos E, Figueras J, Azoulay D. Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. World J Surg 2020;44:3915-22. [PMID: 32661688 DOI: 10.1007/s00268-020-05687-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
419 Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 2020;11:1849-60. [PMID: 32648108 DOI: 10.1007/s13300-020-00867-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
420 Akiyama T, Miyamoto Y, Imai K, Yamashita Y, Nomoto D, Daitoku N, Sakamoto Y, Kiyozumi Y, Tokunaga R, Eto K, Harada K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Baba Y, Yoshida N, Baba H. Fibrosis-4 Index, a Noninvasive Fibrosis Marker, Predicts Survival Outcomes After Hepatectomy for Colorectal Cancer Liver Metastases. Ann Surg Oncol 2020;27:3534-41. [PMID: 32648180 DOI: 10.1245/s10434-020-08828-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
421 Chen Y, Gong J, Zhou W, Jie Y, Li Z, Chong Y, Hu B. A Novel Prediction Model for Significant Liver Fibrosis in Patients with Chronic Hepatitis B. Biomed Res Int 2020;2020:6839137. [PMID: 32695818 DOI: 10.1155/2020/6839137] [Reference Citation Analysis]
422 Kang S, Moon MK, Kim W, Koo BK. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J Cachexia Sarcopenia Muscle 2020;11:1232-41. [PMID: 32638541 DOI: 10.1002/jcsm.12598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
423 Levy JJ, Azizgolshani N, Andersen MJ, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak C, Christensen BC, Vaickus LJ. A Large-Scale Internal Validation Study of Unsupervised Virtual Trichrome Staining Technologies on Non-alcoholic Steatohepatitis Liver Biopsies.. [DOI: 10.1101/2020.07.03.187237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
424 Liang KH, Cheng ML, Lo CJ, Lin YH, Lai MW, Lin WR, Yeh CT. Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: an exploratory study. Sci Rep 2020;10:10926. [PMID: 32616821 DOI: 10.1038/s41598-020-67971-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
425 Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K, Johnson PJ. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:359-70. [PMID: 32519782 DOI: 10.1111/apt.15825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
426 Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, Postel N, Friedrich-Rust M, Hofmann WP; German Hepatitis C-Registry. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. J Viral Hepat 2020;27:690-8. [PMID: 32096310 DOI: 10.1111/jvh.13280] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
427 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
428 Li Q, Huang C, Xu W, Hu Q, Chen L. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2020;99:e20616. [PMID: 32502037 DOI: 10.1097/MD.0000000000020616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
429 Abo El-Khair SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, Abd-Elfattah N, Eldeek B, Farid K. Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study. J Med Virol 2020. [PMID: 32558950 DOI: 10.1002/jmv.26204] [Reference Citation Analysis]
430 Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, Park SW, Cha BS, Lee EJ, Lee YH, Huh KB. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol 2020;19:81. [PMID: 32534588 DOI: 10.1186/s12933-020-01064-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
431 Joseph J. Serum Marker Panels for Predicting Liver Fibrosis - An Update. Clin Biochem Rev 2020;41:67-73. [PMID: 32518428 DOI: 10.33176/AACB-20-00002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
432 Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876 [PMID: 32550761 DOI: 10.3748/wjg.v26.i21.2864] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
433 Li J, Venkatesh SK, Yin M. Advances in Magnetic Resonance Elastography of Liver. Magn Reson Imaging Clin N Am 2020;28:331-40. [PMID: 32624152 DOI: 10.1016/j.mric.2020.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
434 Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-75. [PMID: 31981264 DOI: 10.1111/jvh.13265] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
435 Redman J, Sterling RK. Non-invasive Assessment of Liver Fibrosis. Curr Treat Options Gastro 2020;18:255-269. [DOI: 10.1007/s11938-020-00285-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
436 Wang XP, Wang Y, Ma H, Wang H, Yang DW, Zhao XY, Jin EH, Yang ZH. Assessment of liver fibrosis with liver and spleen magnetic resonance elastography, serum markers in chronic liver disease. Quant Imaging Med Surg 2020;10:1208-22. [PMID: 32550131 DOI: 10.21037/qims-19-849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
437 Šmíd V. Liver fibrosis. Vnitř Lék 2020;66:e36-41. [DOI: 10.36290/vnl.2020.078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
438 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Honda T, Yajima H, Uehara R, Miyazaki O, Hino N, Hirata R, Taura N, Nakao K. Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease. Hepatol Res 2020;50:704-14. [PMID: 32061107 DOI: 10.1111/hepr.13492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
439 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020; 12(5): 220-229 [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
440 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
441 Lee CK, Nastasio S, Mitchell PD, Fawaz R, Elisofon SA, Vakili K, Kim HB, Nguyen D, Jonas MM. Transient elastography assessment of liver allograft fibrosis in pediatric transplant recipients. Pediatr Transplant 2020;24:e13736. [PMID: 32432836 DOI: 10.1111/petr.13736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
442 Hwang J, Yoon HM, Jung AY, Lee JS, Kim KM, Oh SH, Cho YA. Diagnostic Performance of Ultrasound Elastography and Serologic Fibrosis Indices for Evaluation of Hepatic Involvement in Wilson Disease. J Ultrasound Med 2020;39:2231-42. [PMID: 32401363 DOI: 10.1002/jum.15334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
443 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Nakamura Y, Hirooka M, Abe M, Hiasa Y. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J Med Virol. 2020;. [PMID: 32374470 DOI: 10.1002/jmv.25984] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
444 Yong SH, Leem AY, Kim YS, Park MS, Chang J, Kim SU, Jung JY. Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:831-9. [PMID: 32368029 DOI: 10.2147/COPD.S242863] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
445 Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal 2020;34:e23270. [PMID: 32363594 DOI: 10.1002/jcla.23270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
446 Naito S, Fujikawa T, Hasegawa S. Impact of preoperative aspirin continuation on bleeding complications during or after liver resection: Propensity score-matched analysis. J Hepatobiliary Pancreat Sci. 2020;27:830-838. [PMID: 32189437 DOI: 10.1002/jhbp.735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
447 Hanaki T, Uchinaka EI, Yagyu T, Morimoto M, Watanabe J, Miyatani K, Kihara K, Matsunaga T, Yamamoto M, Fukumoto Y, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Hasegawa T, Fujiwara Y. A Novel Noninvasive Method for Predicting Liver Fibrosis by Quantifying the Estrangement of Indocyanine Green Retention Rate and Tc-99m-diethylenetriamine-penta-acetic Acid-galactosyl Human Serum Albumin Scintigraphy. In Vivo 2020;34:1187-93. [PMID: 32354908 DOI: 10.21873/invivo.11891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
448 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología (English Edition) 2020;43:248-255. [DOI: 10.1016/j.gastre.2019.03.027] [Reference Citation Analysis]
449 Maev IV, Kuznetsova EI, Andreev DN, Dicheva DT. [Diagnostic accuracy of predictive indexes of liver fibrosis in patients with chronic hepatitis C]. Ter Arkh 2020;92:24-8. [PMID: 32598714 DOI: 10.26442/00403660.2020.02.000261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
450 Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:658-68. [PMID: 30970434 DOI: 10.5009/gnl18439] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
451 Gu J, Zhang E, Liang B, Zhang Z, Chen X, Huang Z. Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function. World J Surg Oncol 2020;18:79. [PMID: 32326968 DOI: 10.1186/s12957-020-01854-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
452 Wake T, Tateishi R, Fukumoto T, Nakagomi R, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Asaoka Y, Tanaka Y, Otsuka M, Koike K. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS One 2020;15:e0231836. [PMID: 32310974 DOI: 10.1371/journal.pone.0231836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Kinoshita A, Koike K, Mizuno Y, Ogata I, Kobayashi Y, Hasegawa K, Shiraishi K, Yoshida H, Nakata R, Yamada N, Yasuda K. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020;20:578-83. [PMID: 32267087 DOI: 10.1111/ggi.13919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
454 Sugiura A, Joshita S, Yamashita Y, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Nakano Y, Usuda S, Kiyosawa K, Tanaka E, Umemura T. Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. Biomedicines 2020;8:E74. [PMID: 32260271 DOI: 10.3390/biomedicines8040074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
455 Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M, Shibata H, Sato S, Miyaaki H, Nakao K. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Intern Med 2020;59:901-7. [PMID: 32238660 DOI: 10.2169/internalmedicine.3382-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
456 Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, Longerich T, Lackner K, Trauner M, Ferlitsch A, Reiberger T, Weiss KH. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int 2020;40:894-904. [PMID: 31898387 DOI: 10.1111/liv.14368] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
457 Gozdas HT, Ince N. Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2020;32:524-7. [PMID: 31714386 DOI: 10.1097/MEG.0000000000001599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
458 Kallwitz E, Tayo BO, Kuniholm MH, Daviglus M, Zeng D, Isasi CR, Cotler SJ. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. Liver Int 2020;40:889-93. [PMID: 31965669 DOI: 10.1111/liv.14387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
459 Zhou P, Chen B, Miao XY, Zhou JJ, Xiong L, Wen Y, Zou H. Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:823-31. [PMID: 31066014 DOI: 10.1007/s11605-019-04123-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
460 Morales-Arraez D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, Jiménez A, Garcia Dopico JA, Quintero E, Hernández-Guerra M. Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2020;32:528-34. [PMID: 31490420 DOI: 10.1097/MEG.0000000000001534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
461 Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Nam HS, Heo JH, Kim SU. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. Am J Gastroenterol 2020;115:584-95. [PMID: 32141917 DOI: 10.14309/ajg.0000000000000572] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
462 Zirnis AE, Straume Z, Bērziņa R, Māliņa-bambīte J, Derovs A, Zeltiņa I. Establishing Cut-Offs for Non-Invasive Liver Tests to Detect Cirrhosis at a High Sensitivity. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2020;74:118-124. [DOI: 10.2478/prolas-2020-0019] [Reference Citation Analysis]
463 Nah EH, Cho S, Kim S, Kim HS, Cho HI. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J Clin Lab Anal 2020;34:e23316. [PMID: 32227396 DOI: 10.1002/jcla.23316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
464 Ewid M, Sherif H, Allihimy AS, Alharbi SA, Aldrewesh DA, Alkuraydis SA, Abazid R. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes 2020;13:178. [PMID: 32209113 DOI: 10.1186/s13104-020-05031-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
465 Park HE, Lee H, Choi SY, Kim HS, Chung GE. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index. Sci Rep 2020;10:5023. [PMID: 32193478 DOI: 10.1038/s41598-020-61750-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
466 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248-55. [PMID: 32192765 DOI: 10.1016/j.gastrohep.2019.03.017] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
467 Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, Wang J, Ling W. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 2020;299:45-52. [PMID: 32240838 DOI: 10.1016/j.atherosclerosis.2020.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
468 Yan LT, Wang LL, Yao J, Yang YT, Mao XR, Yue W, Mao YW, Zhou W, Chen QF, Chen Y, Duan ZP, Li JF. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore) 2020;99:e19248. [PMID: 32080129 DOI: 10.1097/MD.0000000000019248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
469 Park SH, Kim DJ, Plank LD. Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators. Eur J Clin Nutr 2020;74:1401-9. [PMID: 32152511 DOI: 10.1038/s41430-020-0591-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
470 Assoumou SA, Wang J, Nolen S, Eftekhari Yazdi G, Mayer KH, Puro J, Salomon JA, Linas BP. HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. J Gen Intern Med 2020;35:1477-83. [PMID: 32133577 DOI: 10.1007/s11606-020-05701-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
471 Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 2020;14:225-38. [PMID: 32128704 DOI: 10.1007/s12072-020-10019-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
472 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
473 Sovaila S, Purcarea A, Fauchart JP, Gheonea D, Ciurea T. Hyaluronic Acid, Spleen Size and Prothrombin Time Predict the Existence of High-Risk Esophageal Varices in Non-Viral Cirrhosis in Real Life. Internal Medicine 2020;17:7-19. [DOI: 10.2478/inmed-2020-0097] [Reference Citation Analysis]
474 Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee CH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH, Kim SU. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2020;32:378-85. [PMID: 32011388 DOI: 10.1097/MEG.0000000000001512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
475 Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, Lionello R, La Gamba V, Marascio N, Trecarichi EM, Torti C. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). Medicina (Kaunas) 2020;56:E101. [PMID: 32121135 DOI: 10.3390/medicina56030101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
476 Fayed HM, Mahmoud HS, Elaiw Mohamed Ali A. The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. Clin Exp Gastroenterol 2020;13:53-63. [PMID: 32110084 DOI: 10.2147/CEG.S229689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
477 Saito Y, Okumura Y, Nagashima K, Fukamachi D, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Nishida T, Kojima T, Hanada S, Nomoto K, Sonoda K, Arima K, Takahashi F, Kotani T, Ohkubo K, Fukushima S, Itou S, Kondo K, Ando H, Ohno Y, Onikura M, Hirayama A. Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. J Clin Med 2020;9:E584. [PMID: 32098093 DOI: 10.3390/jcm9020584] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
478 Gorin JB, Malone DFG, Strunz B, Carlsson T, Aleman S, Björkström NK, Falconer K, Sandberg JK. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. Sci Rep 2020;10:2081. [PMID: 32034167 DOI: 10.1038/s41598-020-58768-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
479 Nada A, Abbasy M, Sabry A, Abdu Allah AM, Shehab-Eldeen S, Elnaidany N, Elimam H, Mohamed Ibraheem KI, Essa A. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir. Can J Gastroenterol Hepatol 2020;2020:1632959. [PMID: 32083035 DOI: 10.1155/2020/1632959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
480 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hirata R, Taura N, Nakao K. Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep 2020;12:89-98. [PMID: 32042417 DOI: 10.3892/br.2020.1273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
481 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
482 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
483 Baikpour M, Ozturk A, Dhyani M, Mercaldo ND, Pierce TT, Grajo JR, Samir AE. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol 2020;214:786-91. [PMID: 31939698 DOI: 10.2214/AJR.19.21963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
484 Ohira S, Kanayama N, Toratani M, Ueda Y, Koike Y, Karino T, Shunsuke O, Miyazaki M, Koizumi M, Teshima T. Stereotactic body radiation therapy planning for liver tumors using functional images from dual-energy computed tomography. Radiother Oncol 2020;145:56-62. [PMID: 31923710 DOI: 10.1016/j.radonc.2019.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
485 Parikh NS, Kamel H, Navi BB, Iadecola C, Merkler AE, Jesudian A, Dawson J, Falcone GJ, Sheth KN, Roh DJ, Elkind MSV, Hanley DF, Ziai WC, Murthy SB; VISTA-ICH Collaborators. Liver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage. Stroke 2020;51:830-7. [PMID: 31906832 DOI: 10.1161/STROKEAHA.119.028161] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
486 Chen CH, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019;219:1624-1633. [PMID: 30689910 DOI: 10.1093/infdis/jiy697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
487 Ueno A, Masugi Y, Yamazaki K, Kurebayashi Y, Tsujikawa H, Effendi K, Ojima H, Sakamoto M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 2020;70:140-54. [PMID: 31908112 DOI: 10.1111/pin.12895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
488 Takeuchi H, Sugimoto K, Oshiro H, Iwatsuka K, Kono S, Yoshimasu Y, Kasai Y, Furuichi Y, Sakamaki K, Itoi T. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. Jpn J Med Ultrasonics 2020;47:241-248. [DOI: 10.3179/jjmu.jjmu.k.20] [Reference Citation Analysis]
489 Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS. Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology 2020;158:95-110. [PMID: 31626754 DOI: 10.1053/j.gastro.2019.08.060] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 19.0] [Reference Citation Analysis]
490 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
491 Wang T, Sakaki M, Ichikawa Y, Otoyama Y, Nakajima Y, Sugiura I, Arai J, Kajiwara A, Uozumi S, Shimozuma Y, Uchikoshi M, Yoshida H. Simple Stratification of Hepatocellular Carcinoma Surveillance after Direct-acting Antiviral Therapy for Chronic Hepatitis C. Showa Univ J Med Sci 2020;32:125-133. [DOI: 10.15369/sujms.32.125] [Reference Citation Analysis]
492 Aravind A, Bahirvani AG, Quiambao R, Gonzalo T. Machine Learning Technology for Evaluation of Liver Fibrosis, Inflammation Activity and Steatosis (LIVERFASt<sup>TM</sup>). JILSA 2020;12:31-49. [DOI: 10.4236/jilsa.2020.122003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
493 Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. J Clin Exp Hepatol 2020;10:114-23. [PMID: 32189926 DOI: 10.1016/j.jceh.2019.09.001] [Reference Citation Analysis]
494 Benmassaoud A, Sebastiani G. Fibrosis Assessment via Liver Stiffness Measurements: How Many Patients Are Spared from a Liver Biopsy? Liver Elastography 2020. [DOI: 10.1007/978-3-030-40542-7_49] [Reference Citation Analysis]
495 Hyun Kim K, Kyung Kim B, Yong Park J, Young Kim D, Hoon Ahn S, Han KH, Kim SU. Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. Eur J Gastroenterol Hepatol 2020;32:58-65. [PMID: 31283527 DOI: 10.1097/MEG.0000000000001475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
496 Ishizu Y, Ishigami M, Hayashi K, Honda T, Kuzuya T, Ito T, Fujishiro M. Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. Hepatol Res 2020;50:47-56. [PMID: 31496023 DOI: 10.1111/hepr.13426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
497 Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology 2020;71:44-55. [PMID: 31222774 DOI: 10.1002/hep.30823] [Cited by in Crossref: 141] [Cited by in F6Publishing: 144] [Article Influence: 47.0] [Reference Citation Analysis]
498 Sorin Y, Kon K, Sonoue H, Uchiyama A, Fukuhara K, Yamashina S, Arakawa A, Ikejima K. Decreased Expression of Phosphatase and Tensin Homolog Is Related with the Development of Non-B and Non-C Hepatocellular Carcinoma. Juntendo Medical Journal 2020;66:346-353. [DOI: 10.14789/jmj.2020.66.jmj20-oa01] [Reference Citation Analysis]
499 Zhu YF, Tan YF, Xu X, Zheng JL, Zhang BH, Tang HR, Yang JY. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. Medicine (Baltimore) 2019;98:e18319. [PMID: 31852119 DOI: 10.1097/MD.0000000000018319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
500 Hsu TH, Tsui PH, Yu WT, Huang SF, Tai J, Wan YL, Tai DI. Cutoff Values of Acoustic Radiation Force Impulse Two-Location Measurements in Different Etiologies of Liver Fibrosis. J Med Ultrasound 2019;27:130-4. [PMID: 31867175 DOI: 10.4103/JMU.JMU_7_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
501 López-Martínez R, Arias-García A, Rodríguez-Algarra F, Castellote-Bellés L, Rando-Segura A, Tarraso G, Vargas-Accarino E, Montserrat-Lloan I, Blanco-Grau A, Caballero-Garralda A, Ferrer-Costa R, Pumarola-Sunye T, Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez E, Rodríguez-Frías F. Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination? J Clin Microbiol 2019;58:e01815-19. [PMID: 31694971 DOI: 10.1128/JCM.01815-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
502 Joshita S, Sugiura A, Umemura T, Yamazaki T, Fujimori N, Matsumoto A, Usami Y, Tanaka E. Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection. JGH Open 2020;4:574-81. [PMID: 32782941 DOI: 10.1002/jgh3.12296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
503 Oshida N, Shida T, Oh S, Kim T, Isobe T, Okamoto Y, Kamimaki T, Okada K, Suzuki H, Ariizumi SI, Yamamoto M, Shoda J. Urinary Levels of Titin-N Fragment, a Skeletal Muscle Damage Marker, are Increased in Subjects with Nonalcoholic Fatty Liver Disease. Sci Rep. 2019;9:19498. [PMID: 31862937 DOI: 10.1038/s41598-019-56121-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
504 Cho Y, Choi YI, Oh S, Han J, Joo SK, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease. Hepatol Int 2020;14:270-80. [PMID: 31858403 DOI: 10.1007/s12072-019-10009-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
505 Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T. The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. Aliment Pharmacol Ther 2019;50:1232-8. [PMID: 31588590 DOI: 10.1111/apt.15490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
506 Matos J, Paparo F, Bacigalupo L, Cenderello G, Mussetto I, De Cesari M, Bernardi SP, Cevasco L, Forni GL, Cassola G, Rollandi GA. Noninvasive liver fibrosis assessment in chronic viral hepatitis C: agreement among 1D transient elastography, 2D shear wave elastography, and magnetic resonance elastography. Abdom Radiol (NY) 2019;44:4011-21. [PMID: 31696266 DOI: 10.1007/s00261-019-02295-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
507 Yoo HW, Kim YS, Kim SG, Yoo JJ, Jeong SW, Jang JY, Lee SH, Kim HS, Kim YD, Cheon GJ, Jun B, Kim BS. Usefulness of noninvasive methods including assessment of liver stiffness by 2-dimensional shear wave elastography for predicting esophageal varices. Dig Liver Dis 2019;51:1706-12. [PMID: 31281068 DOI: 10.1016/j.dld.2019.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
508 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. J Microbiol Immunol Infect 2020;53:542-9. [PMID: 31831303 DOI: 10.1016/j.jmii.2019.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
509 Mallet V, Parlati L, Vallet-Pichard A, Terris B, Tsochatzis E, Sogni P, Pol S. [FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients]. Presse Med 2019;48:1484-8. [PMID: 31767251 DOI: 10.1016/j.lpm.2019.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
510 Said M, Soliman Z, Daebes H, M El-Nahaas S, El-Serafy M. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study. Expert Rev Gastroenterol Hepatol 2019;13:1189-95. [PMID: 31702417 DOI: 10.1080/17474124.2019.1690990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
511 Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.AJR Am J Roentgenol. 2020;214:W20-W26. [PMID: 31714842 DOI: 10.2214/AJR.19.21267] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
512 Awori V, Nakigozi G, Kisakye A, Batte J, Anok A, Mayanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Sacktor N, Saylor D. The Veterans Aging Cohort Study Index is not associated with HIV-associated neurocognitive disorders in Uganda. J Neurovirol 2020;26:252-6. [PMID: 31721082 DOI: 10.1007/s13365-019-00806-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
513 Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26:209-15. [PMID: 31679316 DOI: 10.3350/cmh.2019.0065] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 12.8] [Reference Citation Analysis]
514 Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines 2019;7:E87. [PMID: 31684167 DOI: 10.3390/biomedicines7040087] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
515 Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat 2019;26:1266-75. [PMID: 31278795 DOI: 10.1111/jvh.13170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
516 Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol 2019;31:1467-74. [PMID: 31107735 DOI: 10.1097/MEG.0000000000001437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
517 Sonohara F, Yamada S, Tanaka N, Tashiro M, Sunagawa Y, Morimoto D, Tanaka H, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Comparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma. Hepatol Res 2019;49:1305-15. [PMID: 31260575 DOI: 10.1111/hepr.13400] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
518 Inoue J, Akahane T, Nakayama H, Kimura O, Kobayashi T, Kisara N, Sato T, Morosawa T, Izuma M, Kakazu E, Ninomiya M, Iwata T, Takai S, Nakamura T, Sano A, Niitsuma H, Masamune A; THERME Study Group. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. Hepatol Res 2019;49:1263-74. [PMID: 31254482 DOI: 10.1111/hepr.13398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
519 Ji-hee N, Department of Radiology of Busan Paik Hospital, Jung-hoon K. Analysis on Usefulness of Non-invasive Liver Fibrosis Evaluation Method according to the Liver Disease : Focused on H ep atitis C p atients. J Radiol Sci Technol 2019;42:345-350. [DOI: 10.17946/jrst.2019.42.5.345] [Reference Citation Analysis]
520 Hsu SJ, Enkhzaya S, Lin YY, Tseng TC, Khosbayar T, Tsai CH, Wang TS, Enkhtuya D, Ivshinkhorol D, Naranzul N, Jargalsaikhan B, Amarsanaa J, Baatarkhuu O, Kao JH. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. J Formos Med Assoc 2020;119:712-9. [PMID: 31672433 DOI: 10.1016/j.jfma.2019.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
521 Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. J Korean Med Sci 2019;34:e264. [PMID: 31650719 DOI: 10.3346/jkms.2019.34.e264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
522 Ohashi K, Ishikawa T, Hoshii A, Hokari T, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Kikuchi Y, Noguchi H, Hirosawa H, Koyama Y. Efficacy of Physical Activity in Prevention of Muscle Weakness in Patients With Chronic Liver Disease. J Clin Med Res 2019;11:711-9. [PMID: 31636786 DOI: 10.14740/jocmr3978] [Reference Citation Analysis]
523 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 18.5] [Reference Citation Analysis]
524 Zhang W, Huang R, Wang Y, Rao H, Wei L, Su GL, Lok AS. Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis. Hepatol Commun 2019;3:1585-97. [PMID: 31832569 DOI: 10.1002/hep4.1435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
525 Nagao Y, Tanigawa T. Red complex periodontal pathogens are risk factors for liver cirrhosis. Biomed Rep 2019;11:199-206. [PMID: 31632667 DOI: 10.3892/br.2019.1245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
526 Fuster D, Garcia-calvo X, Zuluaga P, Rivas I, Sanvisens A, Tor J, Muga R. Liver Ultrasound Abnormalities in Alcohol Use Disorder. Essentials of Abdominal Ultrasound 2019. [DOI: 10.5772/intechopen.85941] [Reference Citation Analysis]
527 Nickel F, Tapking C, Benner L, Sollors J, Billeter AT, Kenngott HG, Bokhary L, Schmid M, von Frankenberg M, Fischer L. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study. Obes Surg. 2018;28:1342-1350. [PMID: 29119336 DOI: 10.1007/s11695-017-3012-z] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
528 Kallwitz ER, Tayo BO, Kuniholm MH, Cai J, Daviglus M, Cooper RS, Cotler SJ. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clin Gastroenterol Hepatol 2019;17:2301-9. [PMID: 30743004 DOI: 10.1016/j.cgh.2019.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
529 Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatol Res 2019;49:1207-17. [PMID: 31219667 DOI: 10.1111/hepr.13391] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
530 Patel K, Zickmund SL, Jones H, Reid A, Calgaro L, Otero A, Coppler T, Rogal SS. Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era. Dig Dis Sci 2019;64:3001-12. [PMID: 30903364 DOI: 10.1007/s10620-019-05590-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
531 Kusakabe A, Kurosaki M, Itakura J, Joko K, Akahane T, Tsuji K, Kobashi H, Sohda T, Kimura H, Narita R, Furuta K, Izumi N. Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Hepatol Res 2019;49:1121-6. [PMID: 31209976 DOI: 10.1111/hepr.13387] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
532 Li X, Xu H, Gao P. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients. Med Sci Monit 2019;25:7243-50. [PMID: 31558693 DOI: 10.12659/MSM.918784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
533 Izumi G, Takeda A, Yamazawa H, Sasaki O, Kato N, Asai H, Tachibana T, Matsui Y. Forns Index is a predictor of cardiopulmonary bypass time and outcomes in Fontan conversion. Heart Vessels 2020;35:586-92. [PMID: 31562553 DOI: 10.1007/s00380-019-01515-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
534 Park SH, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Jeong C, Suk KT, Kim DJ. Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. Climacteric 2020;23:173-7. [DOI: 10.1080/13697137.2019.1650018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
535 Kawaguchi T, Ide T, Kondo R, Nomura Y, Arinaga-Hino T, Kuwahara R, Amano K, Sano T, Akiba J, Ohshima K, Yano H, Torimura T. Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy. Exp Ther Med 2019;18:3991-4001. [PMID: 31616517 DOI: 10.3892/etm.2019.8024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
536 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P. Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C. PeerJ 2019;7:e7666. [PMID: 31565578 DOI: 10.7717/peerj.7666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
537 Lin PT, Teng W, Jeng WJ, Hsieh YC, Hung CF, Huang CH, Lui KW, Chen YC, Lin CC, Lin SM, Sheen IS, Lin CY. The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. J Formos Med Assoc 2020;119:635-43. [PMID: 31495543 DOI: 10.1016/j.jfma.2019.08.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
538 Kahler CW, Pantalone DW, Mastroleo NR, Liu T, Bove G, Ramratnam B, Monti PM, Mayer KH. Motivational interviewing with personalized feedback to reduce alcohol use in HIV-infected men who have sex with men: A randomized controlled trial. J Consult Clin Psychol 2018;86:645-56. [PMID: 30035581 DOI: 10.1037/ccp0000322] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
539 Xie K, Chen CH, Tsai SP, Lu PJ, Wu H, Zeng Y, Ye Y, Tu H, Wen C, Huang M, Zhang Y, Lee JH, Tsai MK, Wen CP, Wu X. Loss of Life Expectancy by 10 Years or More From Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase. Am J Gastroenterol 2019;114:1478-87. [PMID: 31425154 DOI: 10.14309/ajg.0000000000000332] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
540 Honma Y, Shibata M, Hayashi T, Kusanaga M, Ogino N, Minami S, Kumei S, Oe S, Miyagawa K, Senju M, Matsuoka H, Watanabe T, Hiura M, Abe S, Harada M. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease. Liver Int 2019;39:1641-51. [PMID: 31009141 DOI: 10.1111/liv.14120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
541 Soroida Y, Nakatsuka T, Sato M, Nakagawa H, Tanaka M, Yamauchi N, Wake T, Nakagomi R, Kinoshita MN, Minami T, Uchino K, Enooku K, Asaoka Y, Tanaka Y, Endo M, Nakamura A, Kobayashi T, Kurihara M, Hikita H, Sato M, Gotoh H, Iwai T, Fukayama M, Ikeda H, Tateishi R, Yatomi Y, Koike K. A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform. Ultrasound in Medicine & Biology 2019;45:2363-71. [DOI: 10.1016/j.ultrasmedbio.2019.05.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
542 Mohamed MS, Bassiony MAA, Elsayed Mohamed AF. The role of mean platelet volume in predicting severity and prognosis of liver cirrhosis in Egyptian patients. Egypt J Intern Med 2019;31:261-265. [DOI: 10.4103/ejim.ejim_111_18] [Reference Citation Analysis]
543 Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol 2019;54:829-36. [PMID: 31161311 DOI: 10.1007/s00535-019-01595-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
544 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 19.3] [Reference Citation Analysis]
545 Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, Bai WL, Wang XD, Li ZQ, Chen D, Du WJ, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25(32): 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
546 Debroy P, Lake JE, Malagoli A, Guaraldi G. Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic. J Frailty Aging 2019;8:150-3. [PMID: 31237317 DOI: 10.14283/jfa.2018.37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
547 Levick C, Phillips-Hughes J, Collier J, Banerjee R, Cobbold JF, Wang LM, Piechnik SK, Robson MD, Neubauer S, Barnes E, Pavlides M. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. PLoS One 2019;14:e0221066. [PMID: 31430314 DOI: 10.1371/journal.pone.0221066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
548 Liu X, Xu H, Zhan M, Niu J. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis. Med Sci Monit 2019;25:6174-80. [PMID: 31420961 DOI: 10.12659/MSM.916107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
549 Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chen JJ, Yu ML, Chuang WL. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One 2019;14:e0220663. [PMID: 31393964 DOI: 10.1371/journal.pone.0220663] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
550 Jung JY, Park SK, Oh CM, Chung PW, Ryoo JH. Non-Alcoholic Fatty Liver Disease and Its Association with Depression in Korean General Population. J Korean Med Sci 2019;34:e199. [PMID: 31373184 DOI: 10.3346/jkms.2019.34.e199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
551 Qi X, Li Y, Wang R, Lin L, Li J, Wang L, Zheng S, Sun Y, Zhao L, Fu X, Wang M, Qiu X, Deng H, Hong C, Li Q, Li H, Guo X. Liaoning Score for Prediction of Esophageal Varices in Cirrhotic Patients Who Had Never Undergone Endoscopy: A Multicenter Cross-Sectional Study in Liaoning Province, China. Adv Ther 2019;36:2167-78. [PMID: 31093864 DOI: 10.1007/s12325-019-00967-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
552 Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2019;54:742-51. [PMID: 30848363 DOI: 10.1007/s00535-019-01568-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
553 Arulvijayavani S, Anithasri A, Harini S. COMPARISON OF NON-INVASIVE FIBROSIS SCORES BETWEEN ALCOHOLIC LIVER DISEASE PATIENTS AND HEALTHY NON-ALCOHOLICS IN SOUTH INDIAN POPULATION. jebmh 2019;6:2084-2088. [DOI: 10.18410/jebmh/2019/424] [Reference Citation Analysis]
554 Alem SA, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdom Radiol (NY) 2019;44:2751-8. [PMID: 31028432 DOI: 10.1007/s00261-019-02031-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
555 Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, Koutli E, Michalea S, Manolakopoulos S, Koskinas J, Deutsch M. Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 2019;32:498-503. [PMID: 31474797 DOI: 10.20524/aog.2019.0406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
556 Wei W, Wu X, Zhou J, Sun Y, Kong Y, Yang X. Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients. Comput Math Methods Med 2019;2019:7239780. [PMID: 31428186 DOI: 10.1155/2019/7239780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
557 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
558 Gorin J, Malone DFG, Strunz B, Carlsson T, Aleman S, Björkström NK, Falconer K, Sandberg JK. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.. [DOI: 10.1101/698217] [Reference Citation Analysis]
559 Kato K, Shimada N, Atsukawa M, Abe H, Itokawa N, Matsumoto Y, Agata R, Tsubota A. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. PLoS One 2019;14:e0219022. [PMID: 31291311 DOI: 10.1371/journal.pone.0219022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
560 Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
561 Hsu SJ, Chiu MC, Fang YJ, Yang TH, Yu JJ, Chen CC, Kuo CC, Lee JY, Chen CH, Chen DS, Kao JH. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. J Formos Med Assoc 2019;118:1187-92. [PMID: 31279502 DOI: 10.1016/j.jfma.2019.06.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
562 Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J Hepatol 2019;71:62-70. [PMID: 30797050 DOI: 10.1016/j.jhep.2019.02.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
563 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 18.8] [Reference Citation Analysis]
564 Nishimura T, Iijima H, Nishikawa H, Kondo R, Yano H, Kage M, Aoki T, Nakano C, Yuri Y, Ishii N, Hasegawa K, Takata R, Yoh K, Sakai Y, Takashima T, Aizawa N, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Liver fibrosis markers as assessed by ultrasound elastography and serum samples: A large comparative study in hepatitis virus B and C liver diseases. Hepatol Res 2019;49:721-30. [PMID: 30884015 DOI: 10.1111/hepr.13332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
565 van den Berg EH, Wolters AAB, Dullaart RPF, Moshage H, Zurakowski D, de Meijer VE, Blokzijl H. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 2019;39:1343-54. [PMID: 30968536 DOI: 10.1111/liv.14116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
566 Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M, Tadokoro T, Nomura T, Morishita A, Tsutsui K, Himoto T, Masaki T. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res 2019;49:731-42. [PMID: 30892804 DOI: 10.1111/hepr.13333] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
567 Barocas JA, So-Armah K, Cheng DM, Lioznov D, Baum M, Gallagher K, Fuster D, Gnatienko N, Krupitsky E, Freiberg MS, Samet JH. Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. PLoS One 2019;14:e0218852. [PMID: 31246992 DOI: 10.1371/journal.pone.0218852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
568 Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
569 Yamago H, Hiraoka A, Murakami T, Izumoto H, Ueki H, Ochi M, Aibiki T, Okudaira T, Iwasaki R, Suga Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y, Michitaka K. Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. mol clin onc 2019. [DOI: 10.3892/mco.2019.1888] [Reference Citation Analysis]
570 Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241. [PMID: 29523555 DOI: 10.1161/CIRCIMAGING.117.007241] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
571 Leone S, Lorenzini P, Cozzi-Lepri A, Orofino G, Bernacchia D, Castagna A, Menozzi M, Guaraldi G, Madeddu G, Di Biagio A, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Study Group. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis 2019;38:1857-65. [PMID: 31230205 DOI: 10.1007/s10096-019-03618-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
572 Na SK, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. J Interferon Cytokine Res. 2019;39:703-710. [PMID: 31216229 DOI: 10.1089/jir.2019.0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
573 Futagawa Y, Yanaga K, Kosuge T, Suka M, Isaji S, Hirano S, Murakami Y, Yamamoto M, Yamaue H. Outcomes of pancreaticoduodenectomy in patients with chronic hepatic dysfunction including liver cirrhosis: results of a retrospective multicenter study by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2019;26:310-24. [DOI: 10.1002/jhbp.630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
574 Lu W, Zhang YP, Zhu HG, Zhang T, Zhang L, Gao N, Chang DY, Yin J, Zhou XY, Li MY, Li YT, Li ZZ, He Q, Geng Y. Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection. Br J Biomed Sci. 2019;76:137-142. [PMID: 31062646 DOI: 10.1080/09674845.2019.1615717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
575 Park HJ, Park JY, Jung SM, Song JJ, Park YB, Lee SW. Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BMC Gastroenterol 2019;19:90. [PMID: 31196158 DOI: 10.1186/s12876-019-1007-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
576 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
577 Mitchell LR, Shah N, Selwyn PA. Palliative Care in the Management of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Primary Care Setting. Prim Care 2019;46:433-45. [PMID: 31375191 DOI: 10.1016/j.pop.2019.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
578 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
579 Kolhe KM, Amarapurkar A, Parikh P, Chaubal A, Chauhan S, Khairnar H, Walke S, Ingle M, Pandey V, Shukla A. Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. BMJ Open Gastroenterol. 2019;6:e000288. [PMID: 31275584 DOI: 10.1136/bmjgast-2019-000288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
580 Hanafy AS, Seleem WM, El-Kalla F, AbdAlkhalik Basha M, Abd-Elsalam S. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes Metab Syndr. 2019;13:2272-2278. [PMID: 31235168 DOI: 10.1016/j.dsx.2019.05.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
581 Attallah AM, Albannan MS, Omran MM, Zayed R, Saif S, Farid A, Hassany M, Yosry A, Omran D. A panel of a mitogenic (PDGF), biochemical (albumin) and demographic (age) parameters for the non-invasive assessment of hepatic fibrosis. Br J Biomed Sci 2019;76:105-10. [PMID: 30924403 DOI: 10.1080/09674845.2019.1600325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
582 Liu L, Cao J, Zhong Z, Guo Z, Jiang Y, Bai Y, Xu J. Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients. J Clin Lab Anal 2019;33:e22922. [PMID: 31115929 DOI: 10.1002/jcla.22922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
583 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
584 Chen C, Tsay P, Huang S, Tsui P, Yu W, Hsu T, Tai J, Tai D. Effects of Hepatic Steatosis on Non-Invasive Liver Fibrosis Measurements Between Hepatitis B and Other Etiologies. Applied Sciences 2019;9:1961. [DOI: 10.3390/app9091961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
585 Choi J, Choi GH, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Kim KM. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. Liver Int 2019;39:985-94. [PMID: 30821090 DOI: 10.1111/liv.14082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
586 Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Xu Y, Xie W, Li H, Feng B, Shi G, Chen G, Li H, Zheng H, Cheng J, Wang T, Liu H, Lv F, Shao C, Mao Y, Sun J, Chen T, Han T, Han Y, Wang L, Ou X, Zhang H, Jia J, You H. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat 2019;26:576-85. [PMID: 30624000 DOI: 10.1111/jvh.13058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
587 Silva‐sepulveda JA, Fonseca Y, Vodkin I, Vaughn G, Newbury R, Vavinskaya V, Dwek J, Perry JC, Reshamwala P, Baehling C, Lyon J, Davis C, Lee JW, El‐sabrout H, Shahbah D, Alshawabkeh L, Moore JW, El‐said H. Evaluation of Fontan liver disease: Correlation of transjugular liver biopsy with magnetic resonance and hemodynamics. Congenital Heart Disease 2019;14:600-8. [DOI: 10.1111/chd.12770] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
588 Turcanu A, Pitel E, Dumbrava VT, Tcaciuc E, Donscaia A, Peltec A, Pineau P. Profile of hepatocellular carcinoma in the Republic of Moldova: first-hand information on the presentation, distribution and etiologies. Rom J Intern Med 2019;57:37-46. [PMID: 30375353 DOI: 10.2478/rjim-2018-0026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
589 Gidwani-marszowski R, Owens DK, Lo J, Goldhaber-fiebert JD, Asch SM, Barnett PG. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Appl Health Econ Health Policy 2019;17:513-21. [DOI: 10.1007/s40258-019-00468-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
590 Wakui N, Nagai H, Yoshimine N, Amanuma M, Kobayashi K, Ogino Y, Matsui D, Mukozu T, Matsukiyo Y, Matsui T, Daido Y, Momiyama K, Shinohara M, Kudo T, Maruyama K, Sumino Y, Igarashi Y. Flash Imaging Used in the Post-vascular Phase of Contrast-Enhanced Ultrasonography is Useful for Assessing the Progression in Patients with Hepatitis C Virus-Related Liver Disease. Ultrasound Med Biol. 2019;45:1654-1662. [PMID: 31031037 DOI: 10.1016/j.ultrasmedbio.2019.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
591 Zhang ZQ, Yang B, Zou H, Xiong L, Miao XY, Wen Y, Zhou JJ. ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients. Medicine (Baltimore) 2019;98:e15168. [PMID: 30985698 DOI: 10.1097/MD.0000000000015168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
592 Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expr 2019;19:187-98. [PMID: 31010457 DOI: 10.3727/105221619X15553433838609] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
593 Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes 2019;12:495-503. [PMID: 31114278 DOI: 10.2147/DMSO.S185705] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
594 Nherera B, Mhandire K, Nyazika TK, Makura A, Musarurwa C, Mapondera PT, Stray-pedersen B, Matarira HT. Comparison of non-invasive methods of assessing liver fibrosis in combination ART-experienced Zimbabweans. South Afr j HIV med 2019;20. [DOI: 10.4102/sajhivmed.v20i1.844] [Reference Citation Analysis]
595 Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy 2019;72:129-37. [PMID: 30962036 DOI: 10.1016/j.drugpo.2019.03.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
596 Fayed HM, Ghweil AA, AbdelMeguid MM. Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study. Interdiscip Perspect Infect Dis 2019;2019:9469567. [PMID: 30941170 DOI: 10.1155/2019/9469567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
597 Zhao Y, Thurairajah PH, Kumar R, Tan J, Teo EK, Hsiang JC. Novel non-invasive score to predict cirrhosis in the era of hepatitis C elimination: A population study of ex-substance users in Singapore. Hepatobiliary Pancreat Dis Int 2019;18:143-8. [PMID: 30558838 DOI: 10.1016/j.hbpd.2018.12.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
598 Park DW, Lee YJ, Chang W, Park JH, Lee KH, Kim YH, Kang NK, Chung JW, Jang HY, Ahn S, Kim H, Jeong SH, Kim JW, Jang ES. Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. PLoS One 2019;14:e0212771. [PMID: 30856201 DOI: 10.1371/journal.pone.0212771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
599 Jo MH, Lim TS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. J Clin Med 2019;8:E322. [PMID: 30866538 DOI: 10.3390/jcm8030322] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
600 Park HE, Lee H, Choi SY, Kwak MS, Yang JI, Yim JY, Chung GE. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol 2019;54:271-80. [PMID: 30284617 DOI: 10.1007/s00535-018-1516-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
601 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
602 Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S, Uchida Y, Sohda T, Suzuki H, Yoshida H, Kusakabe A, Tamada T, Kobashi H, Mitsuda A, Kondo M, Shigeno M, Ide Y, Morita A, Kitamura T, Abe T, Izumi N. Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res 2019;49:264-70. [PMID: 30171740 DOI: 10.1111/hepr.13246] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
603 Dharan NJ, Neuhaus J, Rockstroh JK, Peters L, Gordin F, Arenas-Pinto A, Emerson C, Marks K, Hidalgo J, Sarmento-Castro R, Stephan C, Kumarasamy N, Emery S, Matthews GV; INSIGHT START Study Group. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology 2019;69:1135-50. [PMID: 30298608 DOI: 10.1002/hep.30296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
604 Sha FR, Pk MU, Abuelezz NZ, Pervin R, Talukder RI, Begum M, Rahman M. Investigating the Efficiency of APRI, FIB-4, AAR and AARPRI as Noninvasive Markers for Predicting Hepatic Fibrosis in Chronic Hepatitis B Patients in Bangladesh. TOMICROJ 2019;13:34-40. [DOI: 10.2174/1874285801913010034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
605 Castera L. Noninvasive Tests of Liver Fibrosis. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch30] [Reference Citation Analysis]
606 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
607 Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. Int J Mol Sci. 2019;20. [PMID: 30781550 DOI: 10.3390/ijms20040864] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
608 Yokoyama H, Masaki T, Inoue I, Nakamura M, Mezaki Y, Saeki C, Oikawa T, Saruta M, Takahashi H, Ikegami M, Hano H, Ikejima K, Kojima S, Matsuura T. Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease. Heliyon 2019;5:e01231. [PMID: 30815603 DOI: 10.1016/j.heliyon.2019.e01231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
609 Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydoğdu Ö, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turk J Gastroenterol 2018;29:464-72. [PMID: 30249562 DOI: 10.5152/tjg.2018.16597] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
610 Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatol Commun. 2019;3:493-503. [PMID: 30976740 DOI: 10.1002/hep4.1321] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
611 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res 2019;49:136-46. [PMID: 30335208 DOI: 10.1111/hepr.13278] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
612 Lesko CR, Lau B, Chander G, Moore RD. Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use. AIDS 2019;33:285-93. [PMID: 30325772 DOI: 10.1097/QAD.0000000000002054] [Reference Citation Analysis]
613 Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatol Res 2019;49:125-35. [PMID: 30307682 DOI: 10.1111/hepr.13256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
614 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig Liver Dis 2019;51:183-9. [PMID: 30553749 DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
615 Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat 2019;26:224-30. [PMID: 30315694 DOI: 10.1111/jvh.13021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
616 Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouso K, Toyoda H, Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. J Gastroenterol Hepatol 2019;34:436-41. [PMID: 29996177 DOI: 10.1111/jgh.14378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
617 Conti F, Serra C, Vukotic R, Felicani C, Mazzotta E, Gitto S, Vitale G, D'Errico A, Andreone P. Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods. Clin Gastroenterol Hepatol 2019;17:510-517.e3. [PMID: 29935328 DOI: 10.1016/j.cgh.2018.06.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
618 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
619 Tokorodani R, Sumiyoshi T, Okabayashi T, Hata Y, Noda Y, Morita S, Daisaki H, Okada Y, Yasuda E. Liver fibrosis assessment using 99mTc-GSA SPECT/CT fusion imaging. Jpn J Radiol 2019;37:315-20. [DOI: 10.1007/s11604-019-00810-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
620 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Narita S, Toda S, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hori T, Hirata R, Taura N, Nakao K. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. Intern Med 2019;58:1209-15. [PMID: 30626818 DOI: 10.2169/internalmedicine.1514-18] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
621 Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2018;97:e13696. [PMID: 30572498 DOI: 10.1097/MD.0000000000013696] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
622 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Maeda M, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol 2019;34:215-23. [PMID: 30070412 DOI: 10.1111/jgh.14410] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
623 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
624 Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. J Gastroenterol 2019;54:78-86. [PMID: 30019127 DOI: 10.1007/s00535-018-1495-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
625 Morrow LA, Krentz AJ. Early Phase Metabolic Research with Reference to Special Populations. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease 2019. [DOI: 10.1007/978-3-030-11748-1_20] [Reference Citation Analysis]
626 Drapkina OM, Shepel RN, Yakovenko EP, Zyatenkova EV. Non-invasive methods for detection of progressive fibrosis in patients with nonalcoholic fat liver disease. Profil med 2019;22:82. [DOI: 10.17116/profmed20192202182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
627 Lee J, Cho J, Kim J, Uh Y, Youn KJ. Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C. Lab Med Online 2019;9:153. [DOI: 10.3343/lmo.2019.9.3.153] [Reference Citation Analysis]
628 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
629 Zhang ZQ, Huang LW, Chen YP, Wang P. Routine indexes for cirrhosis and significant fibrosis detection in patients with compensated chronic hepatitis B. Dig Liver Dis 2019;51:127-34. [PMID: 30076017 DOI: 10.1016/j.dld.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
630 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology 2019;69:64-75. [PMID: 30019340 DOI: 10.1002/hep.30170] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 17.5] [Reference Citation Analysis]
631 Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY, Sheen IS. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. J Formos Med Assoc 2019;118:1239-46. [PMID: 30581103 DOI: 10.1016/j.jfma.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
632 Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056. [PMID: 30474209 DOI: 10.1111/eci.13056] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
633 Wang TZ, Lin DD, Jin BX, Sun XY, Li N. Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging. Exp Ther Med. 2019;17:1919-1929. [PMID: 30783469 DOI: 10.3892/etm.2018.7117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
634 Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS One 2018;13:e0208903. [PMID: 30540824 DOI: 10.1371/journal.pone.0208903] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
635 Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. J Formos Med Assoc. 2019;118:504-513. [PMID: 30527565 DOI: 10.1016/j.jfma.2018.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
636 Song BG, Sinn DH, Chi S, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol 2018;30:1447-52. [PMID: 30063482 DOI: 10.1097/MEG.0000000000001226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
637 Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2018;53:1276-84. [PMID: 29740665 DOI: 10.1007/s00535-018-1473-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
638 El Din Mohamed Abdo A, Mahmoud Mohy El Din K, El Din Saeed Bedewy E, Abdel Haleem Abo Elwafa R, Adel Abdel Aziz M. Plasma soluble CD 163 level as a marker of oesophageal varices in cirrhotic patients. Alexandria Journal of Medicine 2018;54:567-580. [DOI: 10.1016/j.ajme.2017.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
639 Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018;25:1462-71. [PMID: 30044517 DOI: 10.1111/jvh.12973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
640 Su GL, Glass L, Tapper EB, Van T, Waljee AK, Sales AE. Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology 2018;68:2317-24. [PMID: 29729194 DOI: 10.1002/hep.30074] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 10.4] [Reference Citation Analysis]
641 Huang H, Tang H, Deng H, Shen J, Zhou Q, Xie W, Wu J, Chen J. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients. Transpl Infect Dis 2019;21:e13018. [PMID: 30369001 DOI: 10.1111/tid.13018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
642 Qi X, An W, Liu F, Qi R, Wang L, Liu Y, Liu C, Xiang Y, Hui J, Liu Z, Qi X, Liu C, Peng B, Ding H, Yang Y, He X, Hou J, Tian J, Li Z. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Radiology. 2019;290:370-377. [PMID: 30457484 DOI: 10.1148/radiol.2018180425] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
643 Assoumou SA, Wang J, Tasillo A, Eftekhari Yazdi G, Tsui JI, Strick L, Linas BP. Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016. Am J Prev Med 2019;56:8-16. [PMID: 30467088 DOI: 10.1016/j.amepre.2018.08.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
644 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
645 Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One 2018;13:e0206947. [PMID: 30403744 DOI: 10.1371/journal.pone.0206947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
646 Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, Cho SH, Lin JT, Yu ML, Nguyen MH, Tanaka Y. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:1128-37. [PMID: 30306612 DOI: 10.1111/apt.15006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
647 Chiang HH, Lee CM, Hu TH, Hung CH, Wang JH, Lu SN, Lai HC, Su WP, Lin CH, Peng CY, Chen CH. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int 2018;38:1997-2005. [PMID: 29797410 DOI: 10.1111/liv.13889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
648 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Maeda M, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration. Hepatol Res 2018;48:1020-30. [PMID: 29882396 DOI: 10.1111/hepr.13199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
649 Bellamkonda S, Paruthikunnan SM, Kadavigere R, Sripathi S. Role of Shear Wave Elastography in the Assessment of Fibrosis in Chronic Liver Disease. Journal of Diagnostic Medical Sonography 2018;34:460-465. [DOI: 10.1177/8756479318799340] [Reference Citation Analysis]
650 Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol 2018;69:1155-63. [PMID: 30290973 DOI: 10.1016/j.jhep.2018.07.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
651 Ohashi K, Ishikawa T, Hoshi A, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Seki N, Koyama C, Aoki H, Koyama Y. Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease. J Clin Med Res 2018;10:920-7. [PMID: 30425765 DOI: 10.14740/jocmr3640] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
652 Wang L, Fan YX, Dou XG. Declining diagnostic accuracy of non-invasive fibrosis tests is associated with elevated alanine aminotransferase in chronic hepatitis B. World J Clin Cases 2018; 6(12): 521-530 [PMID: 30397608 DOI: 10.12998/wjcc.v6.i12.521] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
653 Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C; CARDIAC study group. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis 2018;18:518. [PMID: 30326844 DOI: 10.1186/s12879-018-3426-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
654 Chen Y, Li Y, Li N, Fan X, Li C, Zhang P, Han Q, Liu Z. A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels. Dis Markers 2018;2018:3924732. [PMID: 30405859 DOI: 10.1155/2018/3924732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
655 Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PLoS One 2018;13:e0205600. [PMID: 30308053 DOI: 10.1371/journal.pone.0205600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
656 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, He YJ, Lee YH, Huang YH, Hou MC, Huo TI. Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Sci Rep 2018;8:15074. [PMID: 30305679 DOI: 10.1038/s41598-018-33536-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
657 Xu B, Zhou NM, Cao WT, Li XJ. Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2018; 24(37): 4272-4280 [PMID: 30310260 DOI: 10.3748/wjg.v24.i37.4272] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
658 Wang CW, Liao KW, Chan CC, Yu ML, Chuang HY, Chiang HC, Huang PC. Association between urinary thiodiglycolic acid level and hepatic function or fibrosis index in school-aged children living near a petrochemical complex. Environ Pollut 2019;244:648-56. [PMID: 30384070 DOI: 10.1016/j.envpol.2018.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
659 Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H; Japan AIH Study Group. Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS One 2018;13:e0204772. [PMID: 30286131 DOI: 10.1371/journal.pone.0204772] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
660 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
661 Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol 2018;33:1766-72. [PMID: 29514418 DOI: 10.1111/jgh.14142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
662 Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 2018;53:1142-50. [PMID: 29626296 DOI: 10.1007/s00535-018-1455-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
663 Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-ghafar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. International Journal of Infectious Diseases 2018;75:109-114. [DOI: 10.1016/j.ijid.2018.07.025] [Cited by in Crossref: 30] [Article Influence: 6.0] [Reference Citation Analysis]
664 Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-ghafar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. International Journal of Infectious Diseases 2018;75:109-14. [DOI: 10.1016/j.ijid.2018.07.025] [Reference Citation Analysis]
665 Tandon P, Bishay K, Fisher S, Yelle D, Carrigan I, Wooller K, Kelly E. Comparison of clinical outcomes between variceal and non-variceal gastrointestinal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2018;33:1773-9. [PMID: 29601652 DOI: 10.1111/jgh.14147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
666 Wang J, Xia J, Zhang R, Yan X, Yang Y, Zhao X, Chang H, Wang G, Chen G, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat 2018;25:1151-60. [PMID: 29741221 DOI: 10.1111/jvh.12925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
667 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between sarcopenia and osteoporosis in chronic liver disease. Hepatol Res 2018;48:893-904. [PMID: 29734510 DOI: 10.1111/hepr.13192] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
668 Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, Yoon JH. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat 2018;25:1161-71. [PMID: 29741286 DOI: 10.1111/jvh.12927] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
669 Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int 2018;38:1793-802. [PMID: 29575516 DOI: 10.1111/liv.13739] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]
670 Salama M, Nomir M, Fahmi M, El-gayar A, El-shishtawy M. Potential Role of Microfibrillar-Associated Protein 4, Fibrotic Indices and Oxidative Stress in Hepatocellular Carcinoma. Sci Pharm 2018;86:44. [DOI: 10.3390/scipharm86040044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
671 Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine 2018;36:151-8. [PMID: 30268833 DOI: 10.1016/j.ebiom.2018.09.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
672 Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
673 Lee YB, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH. Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Sci Rep 2018;8:13651. [PMID: 30209336 DOI: 10.1038/s41598-018-31839-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
674 Fujita K, Kuroda N, Morishita A, Oura K, Tadokoro T, Nomura T, Yoneyama H, Arai T, Himoto T, Watanabe S, Masaki T. Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. J Clin Med. 2018;7. [PMID: 30208564 DOI: 10.3390/jcm7090267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
675 Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Okuse C, Iwabuchi S, Suzuki M, Itoh F. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res 2018;48:802-9. [PMID: 29504692 DOI: 10.1111/hepr.13074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
676 Das G, Geen J, Johnson R, Abusahmin H. Abnormal serum alanine transaminase levels in adult patients with type 1 diabetes. Pract Diab 2018;35:165-170. [DOI: 10.1002/pdi.2186] [Reference Citation Analysis]
677 Navrotsky AN. [Diagnostic possibilities of methods for the evaluation of liver fibrosis in chronic viral hepatitis]. Ter Arkh 2016;88:149-55. [PMID: 28635835 DOI: 10.17116/terarkh20168811149-155] [Reference Citation Analysis]
678 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. The Relationship between Controlling Nutritional (CONUT) Score and Clinical Markers among Adults with Hepatitis C Virus Related Liver Cirrhosis. Nutrients 2018;10:E1185. [PMID: 30158477 DOI: 10.3390/nu10091185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
679 Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018;4:477-482. [PMID: 30338118 DOI: 10.1002/osp4.294] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
680 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Nakano C, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis. Nutrients 2018;10:E1072. [PMID: 30103528 DOI: 10.3390/nu10081072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
681 Wei R, Wang J, Wang X, Xie G, Wang Y, Zhang H, Peng CY, Rajani C, Kwee S, Liu P, Jia W. Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. EBioMedicine 2018;35:124-32. [PMID: 30100397 DOI: 10.1016/j.ebiom.2018.07.041] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
682 Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-Ghafar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis 2018;75:109-14. [PMID: 30077791 DOI: 10.1016/j.ijid.2018.07.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
683 Wandrer F, Han B, Liebig S, Schlue J, Manns MP, Schulze-Osthoff K, Bantel H. Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection. Aliment Pharmacol Ther 2018;48:270-80. [PMID: 29863282 DOI: 10.1111/apt.14802] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
684 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
685 Han E, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Kim SU. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:300-12. [PMID: 29920701 DOI: 10.1111/apt.14843] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
686 Yeh CS, Hsu CW, Liang KH, Chen YC, Lin CL, Chien RN, Hu TH, Lin WR, Lai MW, Chu YD, Yeh CT. Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. J Gastroenterol Hepatol 2018;33:1530-7. [PMID: 29424069 DOI: 10.1111/jgh.14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
687 Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study. Clin Infect Dis. 2017;65:2050-2056. [PMID: 29020382 DOI: 10.1093/cid/cix716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
688 Assoumou SA, Huang W, Young K, Horsburgh CR, Linas BP. Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital. J Health Care Poor Underserved 2017;28:1333-44. [PMID: 29176099 DOI: 10.1353/hpu.2017.0118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
689 Kromrey ML, Ittermann T, vWahsen C, Plodeck V, Seppelt D, Hoffmann RT, Heiss P, Kühn JP. Reference values of liver volume in Caucasian population and factors influencing liver size. Eur J Radiol 2018;106:32-7. [PMID: 30150048 DOI: 10.1016/j.ejrad.2018.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
690 Yu JH, Kim JK, Lee KS, Lee JI. Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. J Clin Gastroenterol 2018;52:557-62. [PMID: 28863014 DOI: 10.1097/MCG.0000000000000923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
691 Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819-26. [PMID: 29318378 DOI: 10.1007/s00535-017-1425-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 17.4] [Reference Citation Analysis]
692 Su T, Liao C, Liu C, Huang K, Tseng T, Yang H, Liu C, Chen P, Chen D, Kao J. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology 2018;288:293-9. [DOI: 10.1148/radiol.2018171116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
693 Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut 2018;67:1342-50. [PMID: 28615303 DOI: 10.1136/gutjnl-2017-313832] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
694 Kwak MS, Kim KW, Seo H, Chung GE, Yim JY, Kim D. Non-obese fatty liver disease is associated with lacunar infarct. Liver Int 2018;38:1292-9. [PMID: 29220869 DOI: 10.1111/liv.13663] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
695 Majumdar A, Pinzani M. Non-invasive Assessment of Fibrosis and Cirrhosis. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch7] [Reference Citation Analysis]
696 Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, Ofotokun I, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG; Women’s Interagency HIV Study. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. Clin Infect Dis 2017;65:1695-702. [PMID: 29020239 DOI: 10.1093/cid/cix643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
697 Gallacher J, Mcpherson S. Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review. EMJ 2018. [DOI: 10.33590/emj/10314271] [Reference Citation Analysis]
698 Besa C, Wagner M, Lo G, Gordic S, Chatterji M, Kennedy P, Stueck A, Thung S, Babb J, Smith A, Taouli B. Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers. J Magn Reson Imaging 2018;47:1552-61. [PMID: 29193508 DOI: 10.1002/jmri.25911] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
699 Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 2018;67:2244-53. [PMID: 29205416 DOI: 10.1002/hep.29707] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 20.6] [Reference Citation Analysis]
700 Kawaguchi K, Honda M, Ohta H, Terashima T, Shimakami T, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Komura T, Unoura M, Kaneko S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. J Gastroenterol 2018;53:740-51. [PMID: 28849280 DOI: 10.1007/s00535-017-1386-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
701 Zhang Y, Shi Y, Wu R, Wang X, Gao X, Niu J. Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients. Eur J Gastroenterol Hepatol 2018;30:682-6. [PMID: 29462025 DOI: 10.1097/MEG.0000000000001100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
702 Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res 2018;48:529-38. [PMID: 29316051 DOI: 10.1111/hepr.13056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
703 Wu SD, Ding H, Liu LL, Zhuang Y, Liu Y, Cheng LS, Wang SQ, Tseng YJ, Wang JY, Jiang W. Longitudinal monitoring of liver stiffness by acoustic radiation force impulse imaging in patients with chronic hepatitis B receiving entecavir. Clin Res Hepatol Gastroenterol 2018;42:227-36. [PMID: 29066092 DOI: 10.1016/j.clinre.2017.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
704 Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, Hino K. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res 2018;48:521-8. [PMID: 29316028 DOI: 10.1111/hepr.13054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
705 Yue Z, Hong D, Peili F, Yuli Z, Yuan Z, Wenjiao Z, Wenping W. Non-Invasive Assessment of Liver Fibrosis in a Rat Model: Comparison of Shear Wave Elastography with Serologic Tests. Iran J Radiol 2018;15. [DOI: 10.5812/iranjradiol.60665] [Reference Citation Analysis]
706 Miyasaka A, Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanabe D, Hoshino T, Sawara K, Takikawa Y. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1. Intern Med 2018;57:2807-12. [PMID: 29780135 DOI: 10.2169/internalmedicine.0810-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
707 Sanvisens A, Muñoz A, Bolao F, Zuluaga P, Farré M, Jarrin I, Tor J, Muga R. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder? Drug Alcohol Depend 2018;188:180-6. [PMID: 29778771 DOI: 10.1016/j.drugalcdep.2018.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
708 Ikeda H, Watanabe T, Matsumoto N, Hiraishi T, Nakano H, Noguchi Y, Hattori N, Shigefuku R, Yamashita M, Nakahara K, Matsunaga K, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M, Itoh F. Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus. JGH Open 2018;2:87-92. [PMID: 30483569 DOI: 10.1002/jgh3.12052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
709 Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun 2018;2:807-20. [PMID: 30027139 DOI: 10.1002/hep4.1188] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 14.4] [Reference Citation Analysis]
710 Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, Kondo C, Kato K, Hatori T, Hano H, Oikawa T, Emoto N, Abe M, Kage M, Iwakiri K. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res 2018;48:424-32. [PMID: 29274190 DOI: 10.1111/hepr.13046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
711 Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for. J Gastroenterol Hepatol 2018;33:1009-15. [PMID: 29380413 DOI: 10.1111/jgh.14103] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
712 Okubo H, Ando H, Sorin Y, Nakadera E, Fukada H, Morishige J, Miyazaki A, Ikejima K. Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C. PLoS One 2018;13:e0196747. [PMID: 29709031 DOI: 10.1371/journal.pone.0196747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
713 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 164] [Cited by in F6Publishing: 173] [Article Influence: 32.8] [Reference Citation Analysis]
714 Imai H, Kamei H, Onishi Y, Ishizu Y, Ishigami M, Goto H, Ogura Y. Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus. Transplant Proc 2018;50:1431-6. [PMID: 29705278 DOI: 10.1016/j.transproceed.2018.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
715 Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, Ma W, Chen LP, Tseng YJ, Wang JY, Shen XZ, Jiang W. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med. 2018;18:433-443. [PMID: 29696462 DOI: 10.1007/s10238-018-0501-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
716 Strazzulla A, Coppolino G, Barreca GS, Gentile I, Rivoli L, Postorino MC, Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni M, Focà A, Fuiano G, Foti D, Gulletta E, Torti C. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. Clin Mol Hepatol 2018;24:151-62. [PMID: 29684978 DOI: 10.3350/cmh.2017.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
717 Dong Y, Potthoff A, Klinger C, Barreiros AP, Pietrawski D, Dietrich CF. Ultrasound findings in autoimmune hepatitis. World J Gastroenterol 2018; 24(15): 1583-1590 [PMID: 29686465 DOI: 10.3748/wjg.v24.i15.1583] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
718 Caballería L, Torán P, Caballería J. Markers of hepatic fibrosis. Medicina Clínica (English Edition) 2018;150:310-316. [DOI: 10.1016/j.medcle.2018.02.005] [Reference Citation Analysis]
719 Shida T, Akiyama K, Oh S, Sawai A, Isobe T, Okamoto Y, Ishige K, Mizokami Y, Yamagata K, Onizawa K, Tanaka H, Iijima H, Shoda J. Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease. J Gastroenterol 2018;53:535-47. [PMID: 28791501 DOI: 10.1007/s00535-017-1377-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
720 Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol 2018;33:918-25. [PMID: 28914957 DOI: 10.1111/jgh.13989] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
721 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
722 Caballería L, Torán P, Caballería J. Marcadores de fibrosis hepática. Medicina Clínica 2018;150:310-6. [DOI: 10.1016/j.medcli.2017.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
723 Wadhva RK, Haque MM, Luck NH, Tasneem AA, Abbas Z, Mubarak M. Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan. J Transl Int Med 2018;6:38-42. [PMID: 29607303 DOI: 10.2478/jtim-2018-0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
724 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8:4773. [PMID: 29555927 DOI: 10.1038/s41598-018-22923-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
725 Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, Anastos K, Augenbraun M, Fischl M, French AL, Kalapila AG, Karim R, Peters MG, Plankey M, Seaberg EC, Tien PC, Adimora AA. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. AIDS 2018;32:653-61. [PMID: 29334550 DOI: 10.1097/QAD.0000000000001745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
726 Takakusagi S, Sato K, Suzuki Y, Yamazaki Y, Kosone T, Kakizaki S, Kusano M, Takagi H. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia. Intern Med 2018;57:2189-95. [PMID: 29526955 DOI: 10.2169/internalmedicine.9624-17] [Reference Citation Analysis]
727 Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value Health 2018;21:921-30. [PMID: 30098669 DOI: 10.1016/j.jval.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
728 Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol 2018;53:438-48. [PMID: 28744823 DOI: 10.1007/s00535-017-1372-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
729 Lee DH, Lee JM, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK. Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. Liver Cancer 2018;7:65-75. [PMID: 29662834 DOI: 10.1159/000484445] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
730 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 14.4] [Reference Citation Analysis]
731 Scalioni LP, Santos BRD, Spritzer PM, Villela-Nogueira CA, Laura Lewis-Ximenez L, Pollo-Flores P, Bordalo Cathalá Esberard E, Brandão-Mello CE, Lampe E, Villar LM. Impact of vitamin D receptor and binding protein gene polymorphisms in clinical and laboratory data of HCV patients: Cross sectional study. Medicine (Baltimore) 2018;97:e9881. [PMID: 29465575 DOI: 10.1097/MD.0000000000009881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2]